



(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
24.07.2002 Bulletin 2002/30

(51) Int Cl.<sup>7</sup>: C12N 15/12, C07K 14/51,  
A61K 38/18, A61L 27/22,  
A61L 27/54

(21) Application number: 01201546.7

(22) Date of filing: 07.04.1989

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: 08.04.1988 US 179406  
15.08.1988 US 232630  
23.02.1989 US 315342

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
95201872.9 / 0 714 665  
89904986.0 / 0 362 367

(71) Applicant: STRYKER CORPORATION  
Kalamazoo, Michigan 49003-4085 (US)

(72) Inventors:  
• Kuberasampath, Thangavel  
Holliston, MA 01746 (US)

• Oppermann, Hermann  
Medway, Massachusetts 02053 (US)  
• Rueger, David C.  
West Roxbury, Massachusetts 02132 (US)  
• Ozkaynak, Engin  
Milford, Massachusetts 01757 (US)

(74) Representative: Hutchins, Michael Richard et al  
FRY HEATH & SPENCE  
The Old College  
53 High Street  
Horley Surrey RH6 7BN (GB)

## Remarks:

This application was filed on 27 - 04 - 2001 as a  
divisional application to the application mentioned  
under INID code 62.

## (54) Osteogenic devices

(57) Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino

acid composition, solubility properties, structural features, homologues and various other data characterizing osteogenic proteins, and 3) methods of producing osteogenic proteins using recombinant DNA technology.

FIG. 1A-1

```

10      20      30      40      50      60      70
GGAGGTATAGGAGCTCTCTTCGATTTTAGCAAACAGGAGTCCGAAGATCTAAGGAGAGCTGGGGTTTGACTCC
      SacI
85      95      105     115     125     135     145
GAGAGCTCGAGCAGTCCCAAGACCTGGTCTTGACTCAGGAGTTAGACTCCACTCAGAGGCTGACTGTCTCCAGG
      SacI      PflMI
160     170     180     190     200     210     220
GTCTACACCTCTAAGGGCGACACTGGGCTCAAGCAGACTGCCGTTTCTATATGGGATGAGCCTTCACAGGGCAG
235     245     255     265     275     285     295
CCAGTTGGGATGGGTTGAGGTTTGGCTGTAGACATCAGAAACCAAGTCAAATGCGCTTCAACCAAGTAAAAATT
310     320     330     340     350     360     370
CACCAGCCCGCAGAGCTAAGGTTGGGTGGACATTAGGGTTGGTTGATCCAGGAGCTCAACAGTGTCTCTGAGCC
      SacI
385     395     405     415     425     435     445
CCAGCTCCTTCTGCCCCACCCACCATCTTCAGTGTGCTTCTCTCAAGGCCACAGCTGTAGTTGGCCAGGGGG
      PvuII      BglI
460     470     480     490     500     510     520
GCTTCATTATTTTCTGCTCTGGGCACTAGGAGGAAGAATGAATGTCTCTCATGGGCTTTCTTAGGAATGT
      NcoI
535     545     555     565     575     585     595
GGGAACCTTTTCCAGAAGTCTCTATGTCTTTAGTTTGTGTTGGGTCACTTGCCCTTCCTGAACCACTTCCTGAC
610     620     630     640     650     660     670
TCCTGGACAGGATGTGCACTGATGAGCTTAGCTTTGGGGATCTAATAGTCACCTTACAAAGCCTCTTTGAGAAGG
      ApaI      EspI
685     695     705     715     725     735     745
TGACATTGGAACCAAGGCTTGAGCAGACACAACAAAGATTGCAGGGAGGGGCAATTGCAGGTGGAGGAAACGGCAC
      BspMI-
760     770     780     790     800     810     820
ATGCAAGAGCCCTGCGTGGGAGTGAGCTTGGTGTGTTGGTCAATCAGTTGTCAGAGCACACCGGGCCCTGTGAGCA
      ApaI
      EcoO

```

FIG. 1A-2.135

[illegible]

FIG. 1A-3

1A-3  
 CACTAGGGTGAAGCTGATGCTTGGCTCTACGACCGAGGCTCTCTCTGTCGGCGTTCTGTCTCAGAAAGCAGACG  
 a111  
 M1  
 2035 2045 2055 2065 2075 2085 2095  
 8a:1  
 2110 2120 2130 2140 2150 2160 2170  
 CATGGATTCCTCATTTAGGATGACCGCAAGCCGGCTCTCTGCTTCATTTATTTATTTATTTATTTAGAAATGGC  
 col  
 2185 2195 2205 2215 2225 2235 2245  
 CTCCTGCTCTTCACCGAAGCGTGGTGATCGTGCTGATCATGATCCAGCCAGCTTTCAGCGGCTCTCCCATC  
 Tbl1111  
 2260 2270 2280 2290 2300 2310 2320  
 CAGCTCATTAAGCTTGGATATAGCGAAGCACTATAGAGCTGCTCTCTTCCATCTTTTGGGACCAATGAGAG  
 l1ind11  
 2335 2345 2355 2365 2375 2385 2395  
 BstX1  
 CCACCATCTGCTCTTGGCTCTGCTGGGCTCTGCTGCTGAGAGCGATATGCTTGAGGCTTTCACTTGGTCTGGTGA  
 Apa1  
 EcoO  
 2410 2420 2430 2440 2450 2460 2470  
 CCTCTGGTGCGTTCTTTCAGCATGATGGCTTGGAGCTGCTGTCTGATGCTTCTGATGCTTTCCCACTCTCTCT  
 2485 2495 2505 2515 2525 2535 2545  
 CTCCTCTCTCTAGATCTGGATCTATGCGGCTGAGCTACTACTACTACTACTGATGAGGAGGCTGCTGCTCC  
 Mal11  
 2560 2570 2580 2590 2600 2610 2620  
 TGAACCTCTTATGAAACGCTCAAGCAGCATCTGCTGCGATCTGTTGGTATGTCAGCCGACTTGGGCT  
 2635 2645 2655 2665 2675 2685 2695  
 TCAACTGGGCTGGCTGCTGGGCGGACGACGATCTCTGCTCTCTCAAGTGGAGTCTGATGCTGTAAGCC  
 L8T1  
 10:11  
 12a:40

FIG. 1A-4.

**1A-4** 2710 2720 2730 2740 2750 2760 2770  
 ATGCGCTATGCTACTTGTGGGGCCGCTCGCGCTTAAAAAAAATCAAAAATGTGACTTTATGACTCGTTT  
 Aps1  
 EcoD  
 2785 2795 2805 2815 2825 2835 2845  
 GGTATAAAGAGAGCTATAATCTGCCCGTCGACCTTAATTTTCTTCTTCTTAAAGTAAGTAAAGGTTT  
 Dra1  
 2860 2870 2880 2890 2900 2910 2920  
 ATGGGCTCTTTGAGAGCTGTTGTATGTTCTGTGGTGTGGTTCAGTGGTCAAGAGCACTGGGCGGCTCTCA  
 Aps1  
 EcoD  
 2935 2945 2955 2965 2975 2985 2995  
 TTTTCGACATGAGAAACAGTAAACAGTGAAGAAATTCAGTGGAGGCAAGTGTACGAAGCGGCGACGAC  
 3000 3010 3020 3030 3040 3050 3060  
 GATAATGGGATGGAGACATGCTGGGCGACATGGGCCATGTCCAGTAAATTTTCATCGCTGGCTCAGACAGAAAG  
 EcoB NotI  
 3085 3095 3105 3115 3125 3135 3145  
 TCCGATATGATATGAGATTAACGTGCCATACAGGGGACACATCAGTAGGTGTATTTCTCTCTGCGACAGCA  
 3160 3170 3180 3190 3200 3210 3220  
 ACCATAGTTGTAAGAAGCTGTAGGGATTTGTCTCTTTGCTTGAATCAAGGTTCAGAGACCTTGGTATGTGA  
 3235 3245 3255 3265 3275 3285 3295  
 GCGCTCGTTGTATGAACATCATCTGAGCCTTTCTGCTGCTATGATCATCAACCGCTGGCTGAAGTCTTCTAGTGA  
 3310 3320 3330 3340 3350 3360 3370  
 AGAGAGCTCACTACAGAGCATCTCCCTCTTCATTTAAGATATGCTCCCTGCTTTGCTGCTGCTGCTGCT  
 SacI  
 3385 3395 3405 3415 3425 3435 3445  
 GTGTATATGCTGGAGAAATGCTATCTACTATCTCTTCATTTATTTCTGCTCTTTTGAGGGGCAAGGGTTTTCGTT  
 3460 3470 3480 3490 3500 3510 3520  
 CTTGTGTTCCTTTTAAATGCTGTGTTTGTCTTCAAAAGCTTGGTCCCTCTGATATATGAAGATCAAAAAGCCCTCAT  
 3540 3550 3560 3570 3585 3595  
 TGGGATTTGATGATGCTGGAAACAGAGAGTCTCCCAACCTTTCTCTGCTGCTGATGCTGCTGCTGCTG  
 EcoRVNotI

FIG. 1A-5

1A-5

	3610	3620	3630	3640	3650	3660	3670
Ug11	TGCGGATATCCCGCTGAAGGCTGGCGAGGATCTCTCCCGCGCTCGAGGGACACATCTCTATCTCTCTCCACCG						
	3685	3695	3705	3715	3725	3735	3745
Ug11	CTGCTCTTCTGCGCCATGGACACAGGATGCCATCGCCCTCTGTGCGCATCTCCATCAAGTATTTCACGACAGAT						
	3760	3770	3780	3790	3800	3810	3820
	CTCGACGATCAAGTAAGTATTTCCAGGAGTCTGTAAAGATGCGGATCTGATGCTGTTTAAAAAGGCGGACATCT						
	3835	3845	3855	3865	3875	3885	3895
	CTCTCAGAGGCTGCTGATTAAGTAATCTTACACAGGAATGTAGGATGAGTGCGGTGAAATTTGCTTAAAAATCATTCAG						
	3910	3920	3930	3940	3950	3960	3970
	TTGAGGAGGCTGGGGAGAGTATGGATGCTGTGAAGTTTGAATTTCTCATCAAAAATCTGTAAAAAGATCGCT						
	3985	3995	4005	4015	4025	4035	4045
	GCGCTATCTCAGAGATCACAGCGGAGGCTGTGAACAGAGTGCCATCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTG						
	4060	4070	4080	4090	4100	4110	4120
	TTCTCGCAAGATGCTGCTGCTACCTGTTCAAGCAACAGAGAGGCTGGAACTGCTGCTGCTGCTGCTGCTGCTGCTG						
	4135	4145	4155	4165	4175	4185	4195
	AGATCTCTCAACATGATCTGTTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG						
	4210	4220	4230	4240	4250	4260	4270
	CCGCGCTATTCCTGATCTCTTAACTTCGGTCTATTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG						
	4295	4305	4315	4325	4335	4345	4355
	CGACTCTGATCTGTTTCCCTGTCACATCCTCTCTGTGAAGTCTGAGAGAACTCTGCTGACAGCAAGTCTGATGCTG						
	4360	4370	4380	4390	4400	4410	4420
	GUTTCACAGTCTGAGGATCTTACGAAATCTACAGAGGCGGAGCTCTCCCAACAGAGAAATTAACCTGCTGCTGCTG						
	4435	4445	4455	4465	4475	4485	4495
	AATGTGAGATCTGGGCGCTTCTTCCCATCTGATATATGTTGAAGAACTCTATGCTGTTTCCCTGCTGCTGCTGCTG						
	4510	4520	4530	4540	4550	4560	4570
	ACAGAGGATATCCGCAAAATCAATCTGTGCTGTTAAATCTTGAACCAAGGCACTCTGCTGTTGAGGATCTGCTG						

FIG. 1A-6

4585 4595 4605 4615 4625 4635 4645  
 CTGCAGTCATTATTATGCCCAGACAGGATGTTTCTTTATAGAAACGTGGAGGCCAGTTAGAACGACTCACCCTGCT  
 pMI+  
 PstI  
 4660 4670 4680 4690 4700 4710 4720  
 TCTCACCAGTGGCCATGTTTTGGTGTGTGTTTCAGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCT  
 PflMI  
 4735 4745 4755 4765 4775 4785 4795  
 GTGCGCCACGCAGCTCAATGCCATCTCCGTCCTTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACA  
 4810 4820 4830 4840  
 GAAACATGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCCTCCGA

FIG. 1B

CONSENSUS PROBE 20 30 40 50 60 70  
 GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGACTGGATCATCGCCCCCGTGC  
 \*\* \* \* \* \* \*  
 TGTAAGAAGCACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTGAAG  
 OP4 20 30 40 50 60 70  
 80 90 100 110 120 130 140  
 ACTTCGACGCCTACTACTGTCCGGAGCCTGCCAGTTCCCCTCTGCGGATCACTTCAACAGCACCAACCA  
 \*\* \* \* \* \* \*  
 GCTACGCGCGCTACTACTGTGAGGGGGAGTGTGCCTTCCCTCTGAACTCCTACATGAACGCCACCAACCA  
 90 100 110 120 130 140 150  
 150 160 170 180 190 200 210  
 CGCCGTGGTGCAGACCCCTGGTGAACAACATGAACCCCGGAAGGTACCCAAGCCCTGCTGCGTGCCCAACC  
 \* \* \* \* \*  
 CGCCATCGTGCAGACGCTGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGCCACG  
 160 170 180 190 200 210 220  
 220 230 240 250 260 270 280  
 GAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATTCCACCGTGGTGCTGAAGAACTACCAGGAGA  
 \* \* \* \* \*  
 CAGCTCAATGCCATCTCCGTCCTTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGAAACA  
 230 240 250 260 270 280 290  
 290 300 310  
 TGACCGTGGTGGGCTGCGGCTGCCGCTAACTGCA  
 \*\* \* \* \* \* \*  
 TGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCCT  
 300 310 320

## Description

[0001] This invention relates to osteogenic devices, to genes encoding proteins which can induce osteogenesis in mammals and methods for their production using recombinant DNA techniques, to a method of reproducibly purifying osteogenic protein from mammalian bone, and to bone and cartilage repair procedures using the osteogenic device.

[0002] Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

[0003] The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

[0004] Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone *in vivo*.

[0005] This putative bone inductive protein has been shown to have a molecular mass of less than 50 kilodaltons (kD). Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

[0006] The potential utility of these proteins has been widely recognized. It is contemplated that the availability of the protein would revolutionize orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

[0007] The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (Proc. Natl. Acad. Sci. USA (1987) 80). Urist et al. (Proc. Soc. Exp. Biol. Med. (1984) 173:194-199) disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

[0008] Urist et al. (Proc. Natl. Acad. Sci. USA (1984) 81:371-375) disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

[0009] European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

[0010] International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative bone inductive factors produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and apparently expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated. See also Urist et al., EP 0,212,474 entitled Bone Morphogenic Agents.

[0011] Wang et al. (Proc. Nat. Acad. Sci. USA (1988) 85: 9484-9488) discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

[0012] Wozney et al. (Science (1988) 242: 1528-1534) discloses the isolation of full-length cDNA's encoding the human equivalents of three polypeptides originally purified from bovine bone. The authors report that each of the three recombinantly expressed human proteins are independently or in combination capable of inducing cartilage formation. No evidence of bone formation is reported.

[0013] It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein capable of bone induction in allogenic and xenogenic implants. Another object is to provide a reproducible method of isolating osteogenic protein from mammalian bone tissue. Another object is to characterize the protein

responsible for osteogenesis. Another object is to provide natural and recombinant osteogenic proteins capable of inducing endochondral bone formation in mammals, including humans. Yet another object is to provide genes encoding osteogenic proteins and methods for their production using recombinant DNA techniques. Another object is to provide methods for inducing cartilage formation.

**[0014]** These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

### Summary of the Invention

**[0015]** This invention involves osteogenic devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation and bone marrow differentiation. Suitably modified as disclosed herein, the devices also may be used to induce cartilage formation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, containing dispersed osteogenic protein either in its native form as purified from natural sources or produced using recombinant DNA techniques.

**[0016]** Key to these developments was the successful development of a protocol which results in retrieval of active, substantially pure osteogenic protein from mammalian bone, and subsequent elucidation of amino acid sequence and structure data of native osteogenic protein. The protein has a half-maximum bone forming activity of about 0.8 to 1.0 ng per mg of implant. The protein is believed to be a dimer. It appears not to be active when reduced. Various combinations of species of the proteins may exist as heterodimers or homodimers.

**[0017]** The invention provides native forms of osteogenic protein, extracted from bone or produced using recombinant DNA techniques. The substantially pure osteogenic protein may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native protein, no matter how derived. The naturally sourced osteogenic protein in its native form is glycosylated and has an apparent molecular weight of about 30 kD as determined by SDS-PAGE. When reduced, the 30 kD protein gives rise to two glycosylated polypeptide chains having apparent molecular weights of about 16 kD and 18 kD. In the reduced state, the 30 kD protein has no detectable osteogenic activity. The deglycosylated protein, which has osteogenic activity, has an apparent molecular weight of about 27 kD. When reduced, the 27 kD protein gives rise to the two deglycosylated polypeptides have molecular weights of about 14 kD to 16 kD.

**[0018]** Analysis of intact molecules and digestion fragments indicate that the native 30 kD osteogenic protein contains the following amino acid sequences (question marks indicate undetermined residues):

- (1) S-F-D-A-Y-Y-C-S-G-A-C-Q-F-P-M-P-K;
- (2) S-L-K-P-S-N-Y-A-T-I-Q-S-I-V;
- (3) A-C-C-V-P-T-E-L-S-A-I-S-M-L-Y-L-D-E-N-E-K;
- (4) M-S-S-L-S-I-L-F-F-D-E-N-K;
- (5) S-Q-E-L-Y-V-D-F-Q-R;
- (6) F-L-H-C-Q-F-S-E-R-N-S;
- (7) T-V-G-Q-L-N-E-Q-S-S-E-P-N-I-Y;
- (8) L-Y-D-P-M-V-V;
- (9) V-G-V-V-P-G-I-P-E-P-C-C-V-P-E;
- (10) V-D-F-A-D-I-G;
- (11) V-P-K-P-C-C-A-P-T;
- (12) I-N-I-A-N-Y-L;
- (13) D-N-H-V-L-T-M-F-P-I-A-I-N;
- (14) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-?-P;
- (15) D-I-G-?-S-E-W-I-I-?-P;
- (16) S-I-V-R-A-V-G-V-P-G-I-P-E-P-?-?-V;
- (17) D-?-I-V-A-P-P-Q-Y-H-A-F-Y;
- (18) D-E-N-K-N-V-V-L-K-V-Y-P-N-M-T-V-E;
- (19) S-Q-T-L-Q-F-D-E-Q-T-L-K-?-A-R-?-K-Q;
- (20) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-E-P-R-N-?-A-R-R-Y-L;
- (21) A-R-R-K-Q-W-I-E-P-R-N-?-A-?-R-Y-?-?-V-D; and
- (22) R-?-Q-W-I-E-P-?-N-?-A-?-?-Y-L-K-V-D-?-A-?-?-G.

**[0019]** The availability of the protein in substantially pure form, and knowledge of its amino acid sequence and other structural features, enable the identification, cloning, and expression of native genes which encode osteogenic proteins. When properly modified after translation, incorporated in a suitable matrix, and implanted as disclosed herein, these

proteins are operative to induce formation of cartilage and endochondral bone.

[0020] Consensus DNA sequences designed as disclosed herein based on partial sequence data and observed homologies with regulatory proteins disclosed in the literature are useful as probes for extracting genes encoding osteogenic protein from genomic and cDNA libraries. One of the consensus sequences has been used to isolate a heretofore unidentified genomic DNA sequence, portions of which when ligated encode a protein having a region capable of inducing endochondral bone formation. This protein, designated OP1, has an active region having the sequence set forth below.

```

10          1      10      20      30      40
OP1          LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPLNS
              50      60      70
15          YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
          ISVLYFDDSSNVILKKYRNMVVRACGCH

```

A longer active sequence is:

```

20          1      10      20      30      40      -5
OP1          CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPLNS
              50      60      70
25          YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
          ISVLYFDDSSNVILKKYRNMVVRACGCH

```

Fig. 1A discloses the genomic DNA sequence of OP1.

[0021] The probes have also retrieved the DNA sequences identified in PCT/087/01537, referenced above, designated therein as BMPII(b) and BMPIII. The inventors herein have discovered that certain subparts of these genomic DNAs, and BMPIIa, from the same publication, when properly assembled, encode proteins (CBMPIIa, CBMPIIb, and CBMPIII) which have true osteogenic activity, i.e., induce the full cascade of events when properly implanted in a mammal leading to endochondral bone formation. These sequences are:

```

40          1      10      20      30      40
CBMP-2a     CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
              50      60      70
          HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
              80      90     100
          ISMLYLDENEKVVLKKNYQDMVVEGCGCR

45          1      10      20      30      40
CBMP-2b     CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPFLAD
              50      60      70
          HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
              80      90     100
          ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

50          1      10      20      30      40
CBMP-3      CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMPK
              50      60      70
          SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS
              80      90     100
          LSILFFDENKNVVLKVYPNMTVESACR

```

[0022] Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries which encode appropriate amino acid sequences, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active proteins capable of inducing bone formation in mammals including humans.

[0023] The substantially pure osteogenic proteins (i.e., naturally derived or recombinant proteins free of contaminating proteins having no osteoinductive activity) are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles or porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850  $\mu\text{m}$ , preferably 70 - 420  $\mu\text{m}$ . It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable in vivo to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and particulate, deglycosylated (or HF treated), protein extracted, demineralized, xenogenic bone. Optionally, such xenogenic bone powder matrices also may be treated with proteases such as trypsin. Other useful matrix materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

[0024] The osteogenic proteins and implantable osteogenic devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures as demonstrated in animal tests, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

#### Brief Description of the Drawing

[0025] The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1A represents the nucleotide sequence of the genomic copy of osteogenic protein "OP1" gene. The unknown region between 1880 and 1920 actually represents about 1000 nucleotides;

FIGURE 1B is a representation of the hybridization of the consensus gene/probe to the osteogenic protein "OP1" gene;

FIGURE 2 is a collection of plots of protein concentration (as indicated by optical absorption) vs elution volume illustrating the results of bovine osteogenic protein (BOP) fractionation during purification on heparin-Sepharose-I; HAP-Ultragel; sieving gel (Sephacryl 300); and heparin-Sepharose-II;

FIGURE 3 is a photographic reproduction of a Coomassie blue stained SDS polyacrylamide gel of the osteogenic protein under non-reducing (A) and reducing (B) conditions;

FIGURE 4 is a photographic reproduction of a Con A blot of an SDS polyacrylamide gel showing the carbohydrate component of oxidized (A) and reduced (B) 30 kD protein;

FIGURE 5 is a photographic reproduction of an autoradiogram of an SDS polyacrylamide gel of  $^{125}\text{I}$ -labelled glycosylated (A) and deglycosylated (B) osteogenic protein under non-reducing (1) and reducing (2) conditions;

FIGURE 6 is a photographic reproduction of an autoradiogram of an SDS polyacrylamide gel of peptides produced upon the digestion of the 30 kD osteogenic protein with V-8 protease (B), Endo Lys C protease (C), pepsin (D), and trypsin (E). (A) is control;

FIGURE 7 is a collection of HPLC chromatograms of tryptic peptide digestions of 30 kD BOP (A), the 16 kD subunit (B), and the 18 kD subunit (C);

FIGURE 8 is an HPLC chromatogram of an elution profile on reverse phase C-18 HPLC of the samples recovered from the second heparin-Sepharose chromatography step (see FIGURE 2D). Superimposed is the percent bone formation in each fraction;

FIGURE 9 is a gel permeation chromatogram of an elution profile on TSK 3000/2000 gel of the C-18 purified osteogenic peak fraction. Superimposed is the percent bone formation in each fraction;

FIGURE 10 is a collection of graphs of protein concentration (as indicated by optical absorption) vs. elution volume illustrating the results of human protein fractionation on heparin-Sepharose I (A), HAP-Ultrigel (B), TSK 3000/2000 (C), and heparin-Sepharose II (D). Arrows indicate buffer changes;

FIGURE 11 is a graph showing representative dose response curves for bone-inducing activity in samples from various purification steps including reverse phase HPLC on C-18 (A), Heparin-Sepharose II (B), TSK 3000 (C), HAP-ultragel (D), and Heparin-Sepharose I (E);

FIGURE 12 is a bar graph of radiomorphometric analyses of feline bone defect repair after treatment with an osteogenic device (A), carrier control (B), and demineralized bone (C);

FIGURE 13 is a schematic representation of the DNA sequence and corresponding amino acid sequence of a consensus gene/probe for osteogenic protein (COPO);

FIGURE 14 is a graph of osteogenic activity vs. increasing molecular weight showing peak bone forming activity in the 30 kD region of an SDS polyacrylamide gel;

FIGURE 15 is a photographic representation of a Coomassie blue stained SDS gel showing gel purified subunits of the 30 kD protein;

FIGURE 16 is a pair of HPLC chromatograms of Endo Asp N proteinase digests of the 18 kD subunit (A) and the 16 kD subunit (B);

FIGURE 17 is a photographic representation of the histological examination of bone implants in the rat model: carrier alone (A); carrier and glycosylated osteogenic protein (B); and carrier and deglycosylated osteogenic protein (C). Arrows indicate osteoblasts;

FIGURE 18 is a graph illustrating the activity of xenogenic matrix (deglycolylated bovine matrix); and

FIGURES 19A and 19B are bar graphs showing the specific activity of naturally sourced OP before and after gel elution as measured by calcium content vs. increasing concentrations of proteins (dose curve, in ng).

#### Description

**[0026]** Purification protocols have been developed which enable isolation of the osteogenic protein present in crude protein extracts from mammalian bone. While each of the separation steps constitute a known separation technique, it has been discovered that the combination of a sequence of separations exploiting the protein's affinity for heparin and for hydroxyapatite (HAP) in the presence of a denaturant such as urea is key to isolating the pure protein from the crude extract. These critical separation steps are combined with separations on hydrophobic media, gel exclusion chromatography, and elution from SDS PAGE.

**[0027]** The isolation procedure enables the production of significant quantities of substantially pure osteogenic protein from any mammalian species, provided sufficient amounts of fresh bone from the species is available. The empirical development of the procedure, coupled with the availability of fresh calf bone, has enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP has been characterized significantly as set forth below; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat have been studied; it has been shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts; and it may be used to induce formation of endochondral bone in orthopedic defects including non-union fractures. In its native form it is a glycosylated, dimeric protein. However, it is active in deglycosylated form. It has been partially sequenced. Its primary structure includes the amino acid sequences set forth herein.

**[0028]** Elucidation of the amino acid sequence of BOP enables the construction of pools of nucleic acid probes encoding peptide fragments. Also, a consensus nucleic acid sequence designed as disclosed herein based on the amino acid sequence data, inferred codons for the sequences, and observation of partial homology with known genes, also has been used as a probe. The probes may be used to isolate naturally occurring cDNAs which encode active mammalian osteogenic proteins (OP) as described below using standard hybridization methodology. The mRNAs are present in the cytoplasm of cells of various species which are known to synthesize osteogenic proteins. Useful cells



harboring the mRNAs include, for example, osteoblasts from bone or osteosarcoma, hypertrophic chondrocytes, and stem cells. The mRNAs can be used to produce cDNA libraries. Alternatively, relevant DNAs encoding osteogenic protein may be retrieved from cloned genomic DNA libraries from various mammalian species.

[0029] These discoveries enable the construction of DNAs encoding totally novel, non-native protein constructs which individually, and combined are capable of producing true endochondral bone. They also permit expression of the natural material, truncated forms, muteins, analogs, fusion proteins, and various other variants and constructs, from cDNAs retrieved from natural sources or synthesized using the techniques disclosed herein using automated, commercially available equipment. The DNAs may be expressed using well established recombinant DNA technologies in procaryotic or eucaryotic host cells, and may be oxidized and refolded *in vitro* if necessary for biological activity.

[0030] The isolation procedure for obtaining the protein from bone, the retrieval of an osteogenic protein gene, the design and production of recombinant protein, the nature of the matrix, and other material aspects concerning the nature, utility, how to make, and how to use the subject matter claimed herein will be further understood from the following, which constitutes the best method currently known for practicing the various aspects of the invention.

## A - PURIFICATION OF BOP

### A1. Preparation of Demineralized Bone

[0031] Demineralized bovine bone matrix is prepared by previously published procedures (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595). Bovine diaphyseal bones (age 1-10 days) are obtained from a local slaughterhouse and used fresh. The bones are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure with cold water, dipped in cold absolute ethanol, and stored at -20°C. They are then dried and fragmented by crushing and pulverized in a large mill. Care is taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size between 70-420 µm and is defatted by two washes of approximately two hours duration with three volumes of chloroform and methanol (3:1). The particulate bone is then washed with one volume of absolute ethanol and dried over one volume of anhydrous ether. The defatted bone powder (the alternative method is to obtain Bovine Cortical Bone Powder (75-425 µm) from American Biomaterials) is then demineralized with 10 volumes of 0.5 N HCl at 4°C for 40 min., four times. Finally, neutralizing washes are done on the demineralized bone powder with a large volume of water.

### A2. Dissociative Extraction and Ethanol Precipitation

[0032] Demineralized bone matrix thus prepared is dissociatively extracted with 5 volumes of 4 M guanidine-HCl (Gu-HCl), 50mM Tris-HCl, pH 7.0, containing protease inhibitors (5 mM benzamidine, 44 mM 6-aminohexanoic acid, 4.3 mM N-ethylmaleimide, 0.44 mM phenylmethylsulfonylfluoride) for 16 hr. at 4°C. The suspension is filtered. The supernatant is collected and concentrated to one volume using an ultrafiltration hollow fiber membrane (Amicon, YM-10). The concentrate is centrifuged (8,000 x g for 10 min. at 4°C), and the supernatant is then subjected to ethanol precipitation. To one volume of concentrate is added five volumes of cold (-70°C) absolute ethanol (100%), which is then kept at -70°C for 16 hrs. The precipitate is obtained upon centrifugation at 10,000 x g for 10 min. at 4°C. The resulting pellet is resuspended in 4 l of 85% cold ethanol incubated for 60 min. at -70°C and recentrifuged. The precipitate is again resuspended in 85% cold ethanol (2 l), incubated at -70°C for 60 min. and centrifuged. The precipitate is then lyophilized.

### A3. Heparin-Sepharose Chromatography I

[0033] The ethanol precipitated, lyophilized, extracted crude protein is dissolved in 25 volumes of 6 M urea, 50 mM Tris-HCl, pH 7.0 (Buffer A) containing 0.15 M NaCl, and clarified by centrifugation at 8,000 x g for 10 min. The heparin-Sepharose is column-equilibrated with Buffer A. The protein is loaded onto the column and after washing with three column volume of initial buffer (Buffer A containing 0.15 M NaCl), protein is eluted with Buffer A containing 0.5 M NaCl. The absorption of the eluate is monitored continuously at 280 nm. The pool of protein eluted by 0.5 M NaCl (approximately 1 column volumes) is collected and stored at 4°C.

[0034] As shown in FIGURE 2A, most of the protein (about 95%) remains unbound. Approximately 5% of the protein is bound to the column. The unbound fraction has no bone inductive activity when bioassayed as a whole or after a partial purification through Sepharose CL-6B.

### A4. Hydroxyapatite-Ultrogel Chromatography

[0035] The volume of protein eluted by Buffer A containing 0.5 M NaCl from the heparin-Sepharose is applied directly

to a column of hydroxyapatite-ultrogel (HAP-ultrogel) (LKB Instruments), equilibrated with Buffer A containing 0.5 M NaCl. The HAP-ultrogel is treated with Buffer A containing 500 mM Na phosphate prior to equilibration. The unadsorbed protein is collected as an unbound fraction, and the column is washed with three column volumes of Buffer A containing 0.5 M NaCl. The column is subsequently eluted with Buffer A containing 100 mM Na Phosphate (FIGURE 2B).

[0036] The eluted component can induce endochondral bone as measured by alkaline phosphatase activity and histology. As the biologically active protein is bound to HAP in the presence of 6 M urea and 0.5 M NaCl, it is likely that the protein has an affinity for bone mineral and may be displaced only by phosphate ions.

#### A5. Sephacryl S-300 Gel Exclusion Chromatography

[0037] Sephacryl S-300 HR (High Resolution, 5 cm x 100 cm column) is obtained from Pharmacia and equilibrated with 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0. The bound protein fraction from HA-ultrogel is concentrated and exchanged from urea to 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0 via an Amicon ultrafiltration YM-10 membrane. The solution is then filtered with Schleicher and Schuell CENTREX disposable microfilters. A sample aliquot of approximately 15 ml containing approximately 400 mg of protein is loaded onto the column and then eluted with 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0, with a flow rate of 3 ml/min; 12 ml fractions are collected over 8 hours and the concentration of protein is measured at A<sub>280nm</sub> (FIGURE 2C). An aliquot of the individual fractions is bioassayed for bone formation. Those fractions which have shown bone formation and migrate with an apparent molecular weight of less than 35 kD are pooled and concentrated via an Amicon ultrafiltration system with YM-10 membrane.

#### A6. Heparin-Sepharose Chromatography-II

[0038] The pooled osteo-inductive fractions obtained from gel exclusion chromatography are dialysed extensively against distilled water (dH<sub>2</sub>O) and then against 6 M urea, 50 mM Tris-HCl, pH 7.0 (Buffer A) containing 0.1 M NaCl. The dialysate is then cleared through centrifugation. The sample is applied to the heparin-sepharose column (equilibrated with the same buffer). After washing with three column volumes of initial buffer, the column is developed sequentially with Buffer B containing 0.15 M NaCl, and 0.5 M NaCl (FIGURE 2D). The protein eluted by 0.5 M NaCl is collected and dialyzed extensively against distilled water. It is then dialyzed against 30% acetonitrile, 0.1% TFA at 4°C.

#### A7. Reverse Phase HPLC

[0039] The protein is further purified by C-18 Vydac silica-based HPLC column chromatography (particle size 5 µm; pore size 300 Å). The osteoinductive fraction obtained from heparin-sepharose-II chromatograph is loaded onto the column, and washed in 0.1% TFA, 10% acetonitrile for five min. As shown in FIGURE 8, the bound proteins are eluted with a linear gradient of 10-30% acetonitrile over 15 min., 30-50% acetonitrile over 60 min, and 50-70% acetonitrile over 10 min at 22°C with a flow rate of 1.5 ml/min and 1.4 ml samples are collected in polycarbonate tubes. Protein is monitored by absorbance at A<sub>214</sub> nm. Column fractions are tested for the presence of osteoinductive activity, and concanavalin A-blotable proteins. These fractions are then pooled, and characterized biochemically for the presence of 30 kD protein by autoradiography, concanavalin A blotting, and Coomassie blue dye staining. They are then assayed for *in vivo* osteogenic activity. Biological activity is not found in the absence of 30 kD protein.

#### A8. Gel Elution

[0040] The glycosylated or deglycosylated protein is eluted from SDS gels (0.5 mm thickness) for further characterization. <sup>125</sup>I-labelled 30 kD protein is routinely added to each preparation to monitor yields. TABLE 1 shows the various elution buffers that have been tested and the yields of <sup>125</sup>I-labelled protein.

TABLE 1

Elution of 30 kD Protein from SDS Gel		
	Buffer	% Eluted
(1)	dH <sub>2</sub> O	22
(2)	4 M Guanidine-HCl, Tris-HCl, pH 7.0	2
(3)	4 M Guanidine-HCl, Tris-HCl, pH 7.0, 0.5% Triton x 100	93
(4)	0.1% SDS, Tris-HCl, pH 7.0	98

[0041] TABLE 2 lists the steps used to isolate the 30 kD or deglycosylated 27 kD gel-bound protein. The standard

protocol uses diffusion elution using 4M guanidine-HCl containing 0.5% Triton x 100 in Tris-HCl buffer or in Tris-HCl buffer containing 0.1% SDS to achieve greater than 95% elution of the protein from the 27 or 30 kD region of the gel for demonstration of osteogenic activity in vivo as described in later section.

TABLE 2

Preparation of Gel Eluted Protein	
(C-18 Pool or deglycosylated protein plus $^{125}\text{I}$ -labelled 30 kD protein)	
1.	Dry using vacuum centrifugation;
2.	Wash pellet with $\text{H}_2\text{O}$ ;
3.	Dissolve pellet in gel sample buffer (no reducing agent);
4.	Electrophorese on pre-electrophoresed 0.5 mm mini gel;
5.	Cut out 27 or 30 kD protein;
6.	Elute from gel with 0.1% SDS, 50mM Tris-HCl, pH 7.0;
7.	Filter through Centrux membrane;
8.	Concentrate and wash with water in Centricon tube (10 kD membrane).

**[0042]** The overall yield of labelled 30 kD protein from the gel elution protocol is 50 - 60% of the loaded sample. Most of the loss occurs in the electrophoresis step, due to protein aggregation and/or smearing.

**[0043]** The yield is 0.5 to 1.0  $\mu\text{g}$  substantially pure osteogenic protein per kg of bone.

#### A9. Isolation of the 16 kD and 18 kD Species

**[0044]** TABLE 3 summarizes the procedures involved in the preparation of the subunits. Approximately 10  $\mu\text{g}$  of gel eluted 30 kD protein (FIGURE 3) is carboxymethylated and electrophoresed on an SDS-gel. The sample contains  $^{125}\text{I}$ -label to trace yields and to use as an indicator for slicing the 16 kD and 18 kD regions from the gel. FIGURE 15 shows a Coomassie blue stained gel of gel-purified 16 kD and 18 kD proteins.

TABLE 3

Isolation of the Subunits of the 30 kD protein	
(C-18 pool plus $^{125}\text{I}$ -labeled 30 kD protein)	
1.	Electrophorese on SDS gel.
2.	Cut out 30 kD protein.
3.	Elute with 0.1% SDS, 50 mM Tris-HCl, pH 7.0.
4.	Concentrate and wash with $\text{H}_2\text{O}$ in Centricon tube (10 kD membranes).
5.	Electrophorese reduced sample on SDS gel.
6.	Cut out the 16 kD and 18 kD subunits.
7.	Elute with 0.1% SDS, 50 mM Tris-HCl, pH 7.0.
8.	Concentrate and wash with $\text{H}_2\text{O}$ in Centricon tubes.
9.	Reduce and carboxymethylate in 1% SDS, 0.4 M Tris-HCl, pH 8.5.
10.	Concentrate and wash with $\text{H}_2\text{O}$ in Centricon tube.

#### B. Biological Characterization of BOP

##### B1. Gel Slicing:

**[0045]** Gel slicing experiments confirm that the isolated 30 kD protein is the protein responsible for osteogenic activity.

**[0046]** Gels from the last step of the purification are sliced. Protein in each fraction is extracted in 15 mM Tris-HCl, pH 7.0 containing 0.1% SDS or in buffer containing 4 M guanidine-HCl, 0.5% non-ionic detergent (Triton x 100), 50 mM Tris-HCl. The extracted proteins are desalted, concentrated, and assayed for endochondral bone formation activity. The results are set forth in FIGURE 14. From this figure it is clear that the majority of osteogenic activity is due to protein at 30 kD region of the gel. Activity in higher molecular weight regions is apparently due to protein aggregation. These protein aggregates, when reduced, yields the 16 kD and 18 kD species discussed above.

B2. Con A-Sepharose Chromatography:

[0047] A sample containing the 30 kD protein is solubilized using 0.1% SDS, 50 mM Tris-HCl, and is applied to a column of concanavalin A (Con A)-Sepharose equilibrated with the same buffer. The bound material is eluted in SDS Tris-HCl buffer containing 0.5 M alpha-methyl mannoside. After reverse phase chromatography of both the bound and unbound fractions, Con A-bound materials, when implanted, result in extensive bone formation. Further characterization of the bound materials show a Con A-blottable 30 kD protein. Accordingly, the 30 kD glycosylated protein is responsible for the bone forming activity.

B3. Gel Permeation Chromatography:

[0048] TSK-3000/2000 gel permeation chromatography in guanidine-HCl alternately is used to achieve separation of the high specific activity fraction obtained from C-18 chromatography (FIGURE 9). The results demonstrate that the peak of bone inducing activity elutes in fractions containing substantially pure 30 kD protein by Coomassie blue staining. When this fraction is iodinated and subjected to autoradiography, a strong band at 30 kD accounts for 90% of the iodinated proteins. The fraction induces bone formation in vivo at a dose of 50 to 100 ng per implant.

B4. Structural Requirements for Biological ActivityB4-1 Activity after Digestion

[0049] Although the role of 30 kD osteogenic protein is clearly established for bone induction, through analysis of proteolytic cleavage products we have begun to search for a minimum structure that is necessary for activity in vivo. The results of cleavage experiments demonstrate that pepsin treatment fails to destroy bone inducing capacity, whereas trypsin or CNBr completely abolishes the activity.

[0050] An experiment is performed to isolate and identify pepsin digested product responsible for biological activity. The sample used for pepsin digestion was 20% - 30% pure. The buffer used is 0.1% TFA in water. The enzyme to substrate ratio is 1:10. A control sample is made without enzyme. The digestion mixture is incubated at room temperature for 16 hr. The digested product is then separated in 4 M guanidine-HCl using gel permeation chromatography, and the fractions are prepared for in vivo assay. The results demonstrate that active fractions from gel permeation chromatography of the pepsin digest correspond to peptides having an apparent molecular weight range of 8 kD - 10 kD.

B4-2 Unglycosylated Protein is Active

[0051] In order to understand the importance of the carbohydrates moiety with respect to osteogenic activity, the 30 kD protein has been chemically deglycosylated using HF (see below). After analyzing an aliquot of the reaction product by Con A blot to confirm the absence of carbohydrate, the material is assayed for its activity in vivo. The bioassay is positive (i.e., the deglycosylated protein produces a bone formation response as determined by histological examination shown in FIGURE 17C), demonstrating that exposure to HF did not destroy the biological function of the protein, and thus that the OP does not require carbohydrate for biological activity. In addition, the specific activity of the deglycosylated protein is approximately the same as that of the native glycosylated protein.

B5. Specific Activity of BOP

[0052] Experiments were performed 1) to determine the half maximal bone-inducing activity based on calcium content of the implant; 2) to estimate proteins at nanogram levels using a gel scanning method; and 3) to establish dose for half maximal bone inducing activity for gel eluted 30 kD BOP. The results demonstrate that gel eluted substantially pure 30 kD osteogenic protein induces bone at less than 5 ng per implant and exhibits half maximal bone differentiation activity at 20 ng per implant (approx. 25 mg). The purification data suggest that osteogenic protein has been purified from bovine bone to 367,307 fold after the final gel elution step with a specific activity of 47,750 bone forming units per mg of protein.

B5(a) Half Maximal Bone Differentiation Activity

[0053] The bone inducing activity is determined biochemically by the specific activity of alkaline phosphatase and calcium content of the day 12 implant. An increase in the specific activity of alkaline phosphatase indicates the onset of bone formation. Calcium content, on the other hand, is proportional to the amount of bone formed in the implant. The bone formation is therefore calculated by determining calcium content of the implant on day 12 in rats and ex-

pressed as bone forming units, which represent the amount that exhibits half maximal bone inducing activity compared to rat demineralized bone matrix. Bone induction exhibited by intact demineralized rat bone matrix is considered to be the maximal bone-differentiation activity for comparison.

## 5 B5(b) Protein Estimation Using Gel Scanning Techniques

[0054] A standard curve is developed employing known amounts of a standard protein, bovine serum albumin. The protein at varying concentration (50-300 ng) is loaded on a 15% SDS gel, electrophoresed, stained in comassie and destained. The gel is scanned at predetermined settings using a gel scanner at 580 nm. The area covered by the protein band is calculated and a standard curve against concentrations of protein is constructed. A sample with an unknown protein concentration is electrophoresed with BSA as a standard. The lane containing the unknown sample is scanned, and the concentration of protein is determined from the area under the curve.

## 15 B5(c) Gel Elution and Specific Activity

[0055] An aliquot of C-18 highly purified active fraction is subjected to SDS gel and sliced according to molecular weights described in FIGURE 14. Proteins are eluted from the slices in 4 M guanidine-HCl containing 0.5% Triton X-100, desalted, concentrated and assayed for endochondral bone forming activity as determined by calcium content. The C-18 highly active fractions and gel eluted substantially pure 30 kD osteogenic protein are implanted in varying concentrations in order to determine the half maximal bone inducing activity.

[0056] FIGURE 14 shows that the bone inducing activity is due to proteins eluted in the 28-34 kD region. The recovery of activity after the gel elution step is determined by calcium content. FIGURES 19A and 19B represent the bone inducing activity for the various concentrations of 30 kD protein before and after gel elution as estimated by calcium content. The data suggest that the half maximal activity for 30 kD protein before gel elution is 69 ng per 25 mg implant and is 21 ng per 25 mg implant after elution. TABLE 4 describes the yield, total specific activity, and fold purification of osteogenic protein at each step during purification. Approximately 500 ug of heparin sepharose I fraction, 130-150 ug of the HA ultrogel fraction, 10-12 ug of the gel filtration fraction, 4-5 ug of the heparin sepharose II fraction, 0.4-0.5 ug of the C-18 highly purified fraction, and 20-25 ng of the gel eluted, substantially purified fraction is needed per 25 mg of implant for unequivocal bone formation for half maximal activity. Thus, 0.8-1.0 ng purified osteogenic protein per mg. of implant is required to exhibit half maximal bone differentiation activity in vivo.

TABLE 4

PURIFICATION OF BOP				
Purification Steps	Protein (mg.)	Biological Activity Units*	Specific Activity Units/mg.	Purification Fold
Ethanol Precipitate**	30,000#	4,000	0.13	1
Heparin Sepharose I	1,200#	2,400	2.00	15
HA-Ultrogel	300#	2,307	7.69	59
Gel filtration	20#	1,600	80.00	615
Heparin Sepharose II	5#	1,000	200.00	1,538
C-18 HPLC	0.070@	150	2,043.00	15,715
Gel elution	0.004@	191	47,750.00	367,307

Values are calculated from 4 kg of bovine bone matrix (800 g of demineralized matrix).

\* One unit of bone forming activity is defined as the amount that exhibits half maximal bone differentiation activity compared to rat demineralized bone matrix, as determined by calcium content of the implant on day 12 in rats.

# Proteins were measured by absorbance at 280 nm.

@ Proteins were measured by gel scanning method compared to known standard protein, bovine serum albumin.

\*\* Ethanol-precipitated guanidine extract of bovine bone is a weak inducer of bone in rats, possibly due to endogenous inhibitors. This precipitate is subjected to gel filtration and proteins less than 50 kD were separated and used for bioassay.

## C. CHEMICAL CHARACTERIZATION OF BOP

C1. Molecular Weight and Structure

**[0057]** Electrophoresis of the proteins after the final purification step on non-reducing SDS polyacrylamide gels reveals a diffuse band at about 30 kD as detected by both Coomassie blue staining (FIGURE 3A) and autoradiography. **[0058]** In order to extend the analysis of BOP, the protein was examined under reducing conditions. FIGURE 3B shows an SDS gel of BOP in the presence of dithiothreitol. Upon reduction, 30 kD BOP yields two species which are stained with Coomassie blue dye: a 16 kD species and an 18 kD species. Reduction causes loss of biological activity. The two reduced BOP species have been analyzed to determine if they are structurally related. Comparison of the amino acid composition and peptide mapping of the two species (as disclosed below) shows little differences, indicating that the native protein may comprise two chains having significant homology.

C2. Presence of Carbohydrate

**[0059]** The 30 kD protein has been tested for the presence of carbohydrate by Con A blotting after SDS-PAGE and transfer to nitrocellulose paper. The results demonstrate that the 30 kD protein has a high affinity for Con A, indicating that the protein is glycosylated (FIGURE 4A). In addition, the Con A blots provide evidence for a substructure in the 30 kD region of the gel, suggesting heterogeneity due to varying degrees of glycosylation. After reduction (FIGURE 4B), Con A blots show evidence for two major components at 16 kD and 18 kD. In addition, it has been demonstrated that no glycosylated material remains at the 30 kD region after reduction.

**[0060]** In order to confirm the presence of carbohydrate and to estimate the amount of carbohydrate attached, the 30 kD protein is treated with N-glycanase, a deglycosylating enzyme with a broad specificity. Samples of the  $^{125}\text{I}$ -labelled 30 kD protein are incubated with the enzyme in the presence of SDS for 24 hours at 37°C. As observed by SDS-PAGE, the treated samples appear as a prominent species at about 27 kD (FIGURE 5A). Upon reduction, the 27 kD species is reduced to species having a molecular weight of about 14 kD - 16 kD (FIGURE 5B).

**[0061]** To ensure complete deglycosylation of the 30 kD protein, chemical cleavage of the carbohydrate moieties using hydrogen fluoride (HF) is performed. Active osteogenic protein fractions pooled from the C-18 chromatography step are dried *in vacuo* over  $\text{P}_2\text{O}_5$  in a polypropylene tube, and 50  $\mu\text{l}$  freshly distilled anhydrous HF at -70°C is added. After capping the tube tightly, the mixture is kept at 0°C in an ice-bath with occasional agitation for 1 hr. The HF is then evaporated using a continuous stream of dry nitrogen gas. The tube is removed from the ice bath and the residue dried *in vacuo* over  $\text{P}_2\text{O}_5$  and KOH pellets.

**[0062]** Following drying, the samples are dissolved in 100  $\mu\text{l}$  of 50% acetonitrile/0.1% TFA and aliquoted for SDS gel analysis, Con A binding, and biological assay. Aliquots are dried and dissolved in either SDS gel sample buffer in preparation for SDS gel analysis and Con A blotting or 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0 for biological assay.

**[0063]** The results show that samples are completely deglycosylated by the HF treatment: Con A blots after SDS gel electrophoresis and transfer to Immobilon membrane showed no binding of Con A to the treated samples, while untreated controls were strongly positive at 30 kD. Coomassie gels of treated samples showed the presence of a 27 kD band instead of the 30 kD band present in the untreated controls.

C3. Chemical and Enzymatic Cleavage

**[0064]** Cleavage reactions with CNBr are analyzed using Con A binding for detection of fragments associated with carbohydrate. Cleavage reactions are conducted using trifluoroacetic acid (TFA) in the presence and absence of CNBr. Reactions are conducted at 37°C for 18 hours, and the samples are vacuum dried. The samples are washed with water, dissolved in SDS gel sample buffer with reducing agent, boiled and applied to an SDS gel. After electrophoresis, the protein is transferred to Immobilon membrane and visualized by Con A binding. In low concentrations of acid (1%), CNBr cleaves the majority of 16 kD and 18 kD species to one product, a species about 14 kD. In reactions using 10% TFA, a 14 kD species is observed both with and without CNBr.

**[0065]** Four proteolytic enzymes are used in these experiments to examine the digestion products of the 30 kD protein: 1) V-8 protease; 2) Endo Lys C protease; 3) pepsin; and 4) trypsin. Except for pepsin, the digestion buffer for the enzymes is 0.1 M ammonium bicarbonate, pH 8.3. The pepsin reactions are done in 0.1% TFA. The digestion volume is 100  $\mu\text{l}$  and the ratio of enzyme to substrate is 1:10.  $^{125}\text{I}$ -labelled 30 kD osteogenic protein is added for detection. After incubation at 37°C for 16 hr., digestion mixtures are dried down and taken up in gel sample buffer containing dithiothreitol for SDS-PAGE. FIGURE 6 shows an autoradiograph of an SDS gel of the digestion products. The results show that under these conditions, only trypsin digests the reduced 16 kD/18 kD species completely and yields a major species at around 12 kD. Pepsin digestion yields better defined, lower molecular weight species. However, the 16 kD/18 kD fragments were not digested completely. The V-8 digest shows limited digestion with one dom-

inant species at 16 kD.

#### C4. Protein Sequencing

5 **[0066]** To obtain amino acid sequence data, the protein is cleaved with trypsin or Endoproteinase Asp-N (EndoAsp-N). The tryptic digest of reduced and carboxymethylated 30 kD protein (approximately 10 µg) is fractionated by reverse-phase HPLC using a C-8 narrowbore column (13 cm x 2.1 mm ID) with a TFA/acetonitrile gradient and a flow rate of 150 µl/min. The gradient employs (A) 0.06% TFA in water and (B) 0.04% TFA in water and acetonitrile (1:4; v: v). The procedure was 10% B for five min., followed by a linear gradient for 70 min. to 80% B, followed by a linear gradient for 10 min. to 100% B. Fractions containing fragments as determined from the peaks in the HPLC profile (FIGURE 7A) are rechromatographed at least once under the same conditions in order to isolate single components satisfactory for sequence analysis.

**[0067]** The HPLC profiles of the similarly digested 16 kD and 18 kD subunits are shown in FIGURES 7B and 7C, respectively. These peptide maps are similar suggesting that the subunits are identical or are closely related.

15 **[0068]** The 16 kD and 18 kD subunits are digested with EndoAsp-N proteinase. The protein is treated with 0.5 µg EndoAsp-N in 50 mM sodium phosphate buffer, pH 7.8 at 36°C for 20 hr. The conditions for fractionation are the same as those described previously for the 30 kD, 16 kD, and 18 kD digests. The profiles obtained are shown in FIGURES 16A and 16B.

20 **[0069]** Various peptide fragments produced using the foregoing procedures have been analyzed in an automated amino acid sequencer (Applied Biosystems 470A with 120A on-line PTH analysis). The following sequence data has been obtained:

- (1) S-F-D-A-Y-Y-C-S-G-A-C-Q-F-P-M-P-K;
- (2) S-L-K-P-S-N-Y-A-T-I-Q-S-I-V;
- 25 (3) A-C-C-V-P-T-E-L-S-A-I-S-M-L-Y-L-D-E-N-E-K;
- (4) M-S-S-L-S-I-L-F-F-D-E-N-K;
- (5) S-Q-E-L-Y-V-D-F-Q-R;
- (6) F-L-H-C-Q-F-S-E-R-N-S;
- (7) T-V-G-Q-L-N-E-Q-S-S-E-P-N-I-Y;
- 30 (8) L-Y-D-P-M-V-V;
- (9) V-G-V-V-P-G-I-P-E-P-C-C-V-P-E;
- (10) V-D-F-A-D-I-G;
- (11) V-P-K-P-C-C-A-P-T;
- (12) I-N-I-A-N-Y-L;
- 35 (13) D-N-H-V-L-T-M-F-P-I-A-I-N;
- (14) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-?-P;
- (15) D-I-G-?-S-E-W-I-I-?-P;
- (16) S-I-V-R-A-V-G-V-P-G-I-P-E-P-?-?-V;
- (17) D-?-I-V-A-P-P-Q-Y-H-A-F-Y;
- 40 (18) D-E-N-K-N-V-V-L-K-V-Y-P-N-M-T-V-E;
- (19) S-Q-T-L-Q-F-D-E-Q-T-L-K-?-A-R-?-K-Q;
- (20) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-E-P-R-N-?-A-R-R-Y -L;
- (21) A-R-R-K-Q-W-I-E-P-R-N-?-A-?-R-Y-?-?-V-D; and
- (22) R-?-Q-W-I-E-P-?-N-?-A-?-?-Y-L-K-V-D-?-A-?-?-G

#### C5. Amino Acid Analysis

**[0070]** Samples of oxidized (30 kD) and reduced (16 kD and 18 kD) BOP are electrophoresed on a gel and transferred to Immobilon for hydrolysis and amino acid analysis using conventional, commercially available reagents to derivatize samples and HPLC using the PicO Tag (Millipore) system. The composition data generated by amino acid analyses of 30 kD BOP is reproducible, with some variation in the number of residues for a few amino acids, especially cysteine and isoleucine.

**[0071]** Composition data obtained are shown in TABLE 5.

TABLE 5

BOP Amino Acid Analyses			
Amino Acid	30 kD	16 kD	18 kD
Aspartic Acid/ Asparagine	22	14	15
Glutamic Acid/ Glutamine	24	14	16
Serine	24	16	23
Glycine	29	18	26
Histidine	5	*	4
Arginine	13	6	6
Threonine	11	6	7
Alanine	18	11	12
Proline	14	6	6
Tyrosine	11	3	3
Valine	14	8	7
Methionine	3	0	2
Cysteine**	16	14	12
Isoleucine	15	14	10
Leucine	15	8	9
Phenylalanine	7	4	4
Tryptophan	ND	ND	ND
Lysine	12	6	6

\*This result is not integrated because histidine is present in low quantities.

\*\*Cysteine is corrected by percent normally recovered from performic acid hydrolysis of the standard protein.

[0072] The results obtained from the 16 kD and 18 kD subunits, when combined, closely resemble the numbers obtained from the native 30 kD protein. The high figures obtained for glycine and serine are most likely the result of gel elution.

#### D. PURIFICATION OF HUMAN OSTEOGENIC PROTEIN

[0073] Human bone is obtained from the Bone Bank, (Massachusetts General Hospital, Boston, MA), and is milled, defatted, demarrowed and demineralized by the procedure disclosed above. 320 g of mineralized bone matrix yields 70 - 80 g of demineralized bone matrix. Dissociative extraction and ethanol precipitation of the matrix gives 12.5 g of guanidine-HCl extract.

[0074] One third of the ethanol precipitate (0.5 g) is used for gel filtration through 4 M guanidine-HCl (FIGURE 10A). Approximately 70-80 g of ethanol precipitate per run is used. *In vivo* bone inducing activity is localized in the fractions containing proteins in the 30 kD range. They are pooled and equilibrated in 6 M urea, 0.5 M NaCl buffer, and applied directly onto a HAP column; the bound protein is eluted stepwise by using the same buffer containing 100 mM and 500 mM phosphate (FIGURE 10B). Bioassay of HAP bound and unbound fractions demonstrates that only the fraction eluted by 100 mM phosphate has bone inducing activity *in vivo*. The biologically active fraction obtained from HAP chromatography is subjected to heparin-Sepharose affinity chromatography in buffer containing low salt; the bound proteins are eluted by 0.5 M NaCl (FIGURE 10C). Assaying the heparin-Sepharose fractions shows that the bound fraction eluted by 0.5 M NaCl have bone-inducing activity. The active fraction is then subjected to C-18 reverse phase chromatography. (FIGURE 10D).

[0075] The active fraction can then be subjected to SDS-PAGE as noted above to yield a band at about 30 kD comprising substantially pure human osteogenic protein.

#### E. BIOSYNTHETIC PROBES FOR ISOLATION OF GENES ENCODING NATIVE OSTEOGENIC PROTEIN

##### E-1 PROBE DESIGN

[0076] A synthetic consensus gene shown in FIGURE 13 was designed as a hybridization probe based on amino acid predictions from homology with the TGF-beta gene family and using human codon bias as found in human TGF-



beta. The designed consensus sequence was then constructed using known techniques involving assembly of oligonucleotides manufactured in a DNA synthesizer.

[0077] Tryptic peptides derived from BOP and sequenced by Edman degradation provided amino acid sequences that showed strong homology with the Drosophila DPP protein sequence (as inferred from the gene), the Xenopus VG1 protein, and somewhat less homology to inhibin and TGF-beta, as demonstrated below in TABLE 6.

TABLE 6

<u>protein</u>	<u>amino acid sequence</u>	<u>homology</u>
( <u>BOP</u> )	SFDAYYCSGACQFPS ***** * * *	(9/15 matches)
( <u>DPP</u> )	GYDAYYCHGKCPFFL	
<hr/>		
( <u>BOP</u> )	SFDAYYCSGACQFPS * * * * *	(6/15 matches)
( <u>Vgl</u> )	GYMANCYGECPYPL	
<hr/>		
( <u>BOP</u> )	SFDAYYCSGACQFPS * * * * *	(5/15 matches)
( <u>inhibin</u> )	GYHANYCEGECPSHI	
<hr/>		
( <u>BOP</u> )	SFDAYYCSGACQFPS * * * *	(4/15 matches)
( <u>TGF-beta</u> )	GYHANFCLGPCPYIW	
<hr/>		
( <u>BOP</u> )	K/RACCVPTELSAISMLYLDEN ***** * * * *	(12/20 matches)
( <u>Vgl</u> )	LPCCVPTKMSPISMLFYDNN	

5	(BOP)	K/RACCVPTELSAISMLYLDEN * * * * *	(12/20 matches)
	(inhibin)	KSCCVPTKLRPMSMLYYDDG	
10	(BOP)	K/RACCVPTELSAISMLYLDE * * * * *	(6/19 matches)
	(TGF-beta)	APCCVPQALEPLPIVYVVG	
15	(BOP)	K/RACCVPTELSAISMLYLDEN * * * * *	(12/20 matches)
	(DPP)	KACCVPTQLDSVAMLYLNDQ	
20	(BOP)	LYVDF * * * * *	(5/5 matches)
	(DPP)	LYVDF	
25	(BOP)	LYVDF * * * *	(4/5 matches)
	(Vgl)	LYVEF	
30	(BOP)	LYVDF * * *	(4/5 matches)
	(TGF-beta)	LYIDF	
35	(BOP)	LYVDF * *	(2/5 matches)
	(inhibin)	FFVSF	
40	*-match		

[0078] In determining the amino acid sequence of an osteogenic protein (from which the nucleic acid sequence can be determined), the following points were considered: (1) the amino acid sequence determined by Edman degradation of osteogenic protein tryptic fragments is ranked highest as long as it has a strong signal and shows homology or conservative changes when aligned with the other members of the gene family; (2) where the sequence matches for all four proteins, it is used in the synthetic gene sequence; (3) matching amino acids in DPP and Vgl are used; (4) If Vgl or DPP diverged but either one were matched by inhibin or by TGF-beta, this matched amino acid is chosen; (5) where all sequences diverged, the DPP sequence is initially chosen, with a later plan of creating the Vgl sequence by mutagenesis kept as a possibility. In addition, the consensus sequence is designed to preserve the disulfide crosslinking and the apparent structural homology.

[0079] One purpose of the originally designed synthetic consensus gene sequence, designated COP0, (see FIGURE 13), was to serve as a probe to isolate natural genes. For this reason the DNA was designed using human codon bias. Alternatively, probes may be constructed using conventional techniques comprising a group of sequences of nucleotides which encode any portion of the amino acid sequence of the osteogenic protein produced in accordance with the foregoing isolation procedure. Use of such pools of probes also will enable isolation of a DNA encoding the intact

protein.

## E-2 Retrieval of Genes Encoding Osteogenic Protein from Genomic Library

**[0080]** A human genomic library (Maniatis-library) carried in lambda phage (Charon 4A) was screened using the COP0 consensus gene as probe. The initial screening was of 500,000 plaques (10 plates of 50,000 each). Areas giving hybridization signal were punched out from the plates, phage particles were eluted and plated again at a density of 2000-3000 plaques per plate. A second hybridization yielded plaques which were plated once more, this time at a density of ca 100 plaques per plate allowing isolation of pure clones. The probe (COP0) is a 300 base pair BamHI-PstI fragment restricted from an amplification plasmid which was labeled using alpha 32 dCTP according to the random priming method of Feinberg and Vogelstein (1984) Anal. Biochem. 137: 266-267. Prehybridization was done for 1 hr in 5x SSPE, 10x Denhardt's mix, 0.5% SDS at 50°C. Hybridization was overnight in the same solution as above plus probe. The washing of nitrocellulose membranes was done, once cold for 5 min. in 1x SSPE with 0.1% SDS and twice at 50°C for 2 x 30 min. in the same solution. Using this procedure, twenty-four positive clones were found. Two contained a gene never before reported designated OP1, osteogenic protein-1 described below. Two others yielded the genes corresponding to BMP-2b, one yielded BMP-3 (see PCT US 87/01537).

**[0081]** Southern blot analysis of lambda #13 DNA showed that an approximately 3kb BamHI fragment hybridized to the probe. (See FIGURE 1B). This fragment was isolated and subcloned into a bluescript vector (at the BamHI site). The clone was further analyzed by Southern blotting and hybridization to the COP0 probe. This showed that a 1 kb (approx.) EcoRI fragment strongly hybridized to the probe. This fragment was subcloned into the EcoRI site of a blue-script vector, and sequenced. Analysis of this sequence showed that the fragment encoded the carboxy terminus of a protein, named osteogenic protein-1 (OP1). The protein was identified by amino acid homology with the TGF-beta family. For this comparison cysteine patterns were used and then the adjacent amino acids were compared. Consensus splice signals were found where amino acid homologies ended, designating exon intron boundaries. Three exons were combined to obtain a functional TGF-beta-like domain containing seven cysteines. Two introns were deleted by looping out via primers bridging the exons using the single stranded mutagenesis method of Kunkel. Also, upstream of the first cysteine, an EcoRI site and an asp-pro junction for acid cleavage were introduced, and at the 3' end a PstI site was added by the same technique. Further sequence information (penultimate exon) was obtained by sequencing the entire insert. The sequencing was done by generating a set of unidirectionally deleted clones (Ozkaynak, E., and Putney, S. (1987) Biotechniques, 5:770-773). The obtained sequence covers about 80% of the TGF-beta-like region of OP1 and is set forth in FIGURE 1A. The complete sequence of the TGF-beta like region was obtained by first subcloning all EcoRI generated fragments of lambda clone #13 DNA and sequencing a 4 kb fragment that includes the first portion of the TGF-beta like region (third exon counting from end) as well as sequences characterized earlier. The gene on an EcoRI to PstI fragment was inserted into an E. coli expression vector controlled by the trp promoter-operator to produce a modified trp LE fusion protein with an acid cleavage site. The OP1 gene encodes amino acids corresponding substantially to a peptide found in sequences of naturally sourced material. The amino acid sequence of what is believed to be its active region is set forth below:

```

      1      10      20      30      40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
  
```

A longer active sequence is:

-5  
HQRQA

OP1                    1                    10                    20                    30                    40

CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPFLNS

50                    60                    70

YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA

80                    90                    100

ISVLYFDDSSNVILKKYRNMVVRACGCH

[0082] The amino acid sequence of what is believed to be the active regions encoded by the other three native genes retrieved using the consensus probe are:

CBMP-2a                    1                    10                    20                    30                    40

CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECFPFLAD

50                    60                    70

HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA

80                    90                    100

ISMLYLDENEKVVLKNYQDMVVEGCGCR

CBMP-2b                    1                    10                    20                    30                    40

CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCFPFLAD

50                    60                    70

HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA

80                    90                    100

ISMLYLDEYDKVVLKNYQEMVVEGCGCR

CBMP-3                    1                    10                    20                    30                    40

CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK

50                    60                    70

SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS

80                    90                    100

LSILFFDENKNVVLKVYPNMTVESACR

### E-3 Probing cDNA Library

[0083] Another example of the use of pools of probes to enable isolation of a DNA encoding the intact protein is shown by the following. Cells known to express the protein (e.g., osteoblasts or osteosarcoma) are extracted to isolate total cytoplasmic RNA. An oligo-dT column can be used to isolate mRNA. This mRNA can be size fractionated by, for example, gel electrophoresis. The fraction which includes the mRNA of interest may be determined by inducing transient expression in a suitable host cell and testing for the presence of osteogenic protein using, for example, antibody raised against peptides derived from the tryptic fragments of osteogenic protein in an immunoassay. The mRNA fraction is then reverse transcribed to single stranded cDNA using reverse transcriptase; a second complementary DNA strand can then be synthesized using the cDNA as a template. The double-standard DNA is then ligated into vectors which are used to transfect bacteria to produce a cDNA library.

[0084] The radiolabelled consensus sequence, portions thereof, and/or synthetic deoxy oligonucleotides complementary to codons for the known amino acid sequences in the osteogenic protein may be used to identify which of the DNAs in the cDNA library encode the full length osteogenic protein by standard DNA-DNA hybridization techniques.

[0085] The cDNA may then be integrated in an expression vector and transfected into an appropriate host cell for protein expression. The host may be a prokaryotic or eucaryotic cell since the former's inability to glycosylate osteogenic protein will not effect the protein's enzymatic activity. Useful host cells include *Saccharomyces*, *E. coli*, and various mammalian cell cultures. The vector may additionally encode various signal sequences for protein secretion and/or may encode osteogenic protein as a fusion protein. After being translated, protein may be purified from the cells or recovered from the culture medium.

#### E4. Gene Preparation

**[0086]** Natural gene sequences and cDNAs retrieved as described above may be used for expression. The genes above may also be produced by assembly of chemically synthesized oligonucleotides. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer (TBE). The DNA is then electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE.

#### E5. Expression

**[0087]** The genes can be expressed in appropriate prokaryotic hosts such as various strains of E. coli, and also in bacillus, yeasts, and various animal cells such as CHO, myeloma, etc. Generally, expression may be achieved using many cell types and expression systems well known to those skilled in the art. For example, if the gene is to be expressed in E. coli, an expression vector based on pBR322 and containing a synthetic trp promoter operator and the modified trp LE leader may be used. The vector can be opened at the EcoRI and PSTI restriction sites, and, for example, an OP gene fragment can be inserted between these two sites. The OP protein is joined to the leader protein via a hinge region having the sequence Asp-Pro. This hinge permits chemical cleavage of the fusion protein with dilute acid at the Asp-Pro site.

#### E6. Production of Active Proteins

**[0088]** The following procedure may be followed for production of active recombinant proteins. E. coli cells containing the fusion proteins are lysed. The fusion proteins are purified by differential solubilization. Cleavage is conducted with dilute acid, and the resulting cleavage products are passed through a Sephacryl-200HR or SP Trisacryl column to separate the cleaved proteins. The reduced OP fractions are then subjected to HPLC on a semi-prep C-18 column.

**[0089]** Conditions for refolding of OP were at pH 8.0 using 50 mM Tris-HCl and 6M Gu-HCl. Samples were refolded for 18 hours at 4°C.

**[0090]** These procedures have been used to express in E. coli on the active protein designated OP1 having the amino acid sequence set forth above (longer species).

**[0091]** Refolding may not be required if the proteins are expressed in animal cells.

### MATRIX PREPARATION

#### A. General Consideration of Matrix Properties

**[0092]** The carrier described in the bioassay section, *infra*, may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., HAP, collagen, tricalcium phosphate, or polylactic acid, polyglycolic acid and various copolymers thereof). Also xenogeneic bone may be used if pretreated as described below.

**[0093]** Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 and 420 µm elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate osteogenic protein onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

**[0094]** The sequential cellular reactions at the interface of the bone matrix/OP implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

**[0095]** A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible *in vivo* and biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Biocompatibility requires that the matrix not induce significant inflammation when implanted and not be rejected by the host animal. Biodegradability requires that the matrix be slowly absorbed by the body of the host during development of new bone or cartilage. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates *in vivo*. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

**[0096]** Matrix geometry, particle size, the presence of surface charge, and porosity or the presence of interstices

among the particles of a size sufficient to permit cell infiltration, are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

[0097] The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogeneic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particles and the dispersed osteogenic protein.

#### B. Preparation of Biologically Active Allogenic Matrix

[0098] Demineralized bone matrix is prepared from the dehydrated diaphyseal shafts of rat femur and tibia as described herein to produce a bone particle size which pass through a 420  $\mu$  sieve. The bone particles are subjected to dissociative extraction with 4 M guanidine-HCl. Such treatment results in a complete loss of the inherent ability of the bone matrix to induce endochondral bone differentiation. The remaining insoluble material is used to fabricate the matrix. The material is mostly collagenous in nature, and upon implantation, does not induce cartilage and bone. All new preparations are tested for mineral content and false positives before use. The total loss of biological activity of bone matrix is restored when an active osteoinductive protein fraction or a pure protein is reconstituted with the biologically inactive insoluble collagenous matrix. The osteoinductive protein can be obtained from any vertebrate, e.g., bovine, porcine, monkey, or human, or produced using recombinant DNA techniques.

#### C. Preparation of Deglycosylated Bone Matrix for Use in Xenogenic Implant

[0099] When osteogenic protein is reconstituted with collagenous bone matrix from other species and implanted in rat, no bone is formed. This suggests that while the osteogenic protein is xenogenic (not species specific), the matrix is species specific and cannot be implanted cross species perhaps due to intrinsic immunogenic or inhibitory components. Thus, heretofore, for bone-based matrices, in order for the osteogenic protein to exhibit its full bone inducing activity, a species specific collagenous bone matrix was required.

[0100] The major component of all bone matrices is Type I collagen. In addition to collagen, extracted bone includes non-collagenous proteins which may account for 5% of its mass. Many non-collagenous components of bone matrix are glycoproteins. Although the biological significance of the glycoproteins in bone formation is not known, they may present themselves as potent antigens by virtue of their carbohydrate content and may constitute immunogenic and/or inhibitory components that are present in xenogenic matrix.

[0101] It has now been discovered that a collagenous bone matrix may be used as a carrier to effect bone inducing activity in xenogenic implants, if one first removes the immunogenic and inhibitory components from the matrix. The matrix is deglycosylated chemically using, for example, hydrogen fluoride to achieve this purpose.

[0102] Bovine bone residue prepared as described above is sieved, and particles of the 74-420  $\mu$ m are collected. The sample is dried in vacuo over  $P_2O_5$ , transferred to the reaction vessel and anhydrous hydrogen fluoride (HF) (10-20 ml/g of matrix) is then distilled onto the sample at -70°C. The vessel is allowed to warm to 0°C and the reaction mixture is stirred at this temperature for 120 min. After evaporation of the HF in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid.

[0103] Extent of deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with HF, after washing the samples appropriately to remove non-covalently bound carbohydrates.

[0104] The deglycosylated bone matrix is next treated as set forth below:

1) suspend in TBS (Tris-buffered Saline) 1g/200 ml and stir at 4°C for 2 hrs or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS), and stir at RT for 30 min.;

2) centrifuge and wash with TBS or UTBS as in step 1); and

3) centrifuge; discard supernatant; water wash residue; and then lyophilize.

#### FABRICATION OF OSTEOGENIC DEVICE

[0105] Fabrication of osteogenic devices using any of the matrices set forth above with any of the osteogenic proteins described above may be performed as follows.

A. Ethanol precipitation

[0106] In this procedure, matrix was added to osteogenic protein in guanidine-HCl. Samples were vortexed and incubated at a low temperature. Samples were then further vortexed. Cold absolute ethanol was added to the mixture which was then stirred and incubated. After centrifugation (microfuge high speed) the supernatant was discarded. The reconstituted matrix was washed with cold concentrated ethanol in water and then lyophilized.

B. Acetonitrile Trifluoroacetic Acid Lyophilization

[0107] In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution was added to the carrier. Samples were vigorously vortexed many times and then lyophilized.

C. Urea Lyophilization

[0108] For those proteins that are prepared in urea buffer, the protein is mixed with the matrix, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

IN VIVO RAT BIOASSAY

[0109] Substantially pure BOP, BOP-rich extracts comprising protein having the properties set forth above, and several of the recombinant proteins have been incorporated in matrices to produce osteogenic devices, and assayed in rat for endochondral bone. Studies in rats show the osteogenic effect to be dependent on the dose of osteogenic protein dispersed in the osteogenic device. No activity is observed if the matrix is implanted alone. The following sets forth guidelines for how the osteogenic devices disclosed herein might be assayed for determining active fractions of osteogenic protein when employing the isolation procedure of the invention, and evaluating protein constructs and matrices for biological activity.

A. Subcutaneous Implantation

[0110] The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by reference, is used to monitor the purification protocols for endochondral bone differentiation activity. This assay consists of implanting the test samples in subcutaneous sites in allogeneic recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

B. Cellular Events

[0111] The implant model in rats exhibits a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

C. Histological Evaluation

[0112] Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in parafilm, cut into 6-8 mm sections. Staining with toluidine blue or hematoxylin/eosin demonstrates clearly the ultimate development of endochondral bone. Twelve day implants are usually sufficient to determine whether the implants show bone inducing activity.

D. Biological Markers

[0113] Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be deter-

mined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology should have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the implants are removed from the rat. Alternatively the amount of bone formation can be determined by measuring the calcium content of the implant.

[0114] Implants containing osteogenic protein at several levels of purity have been tested to determine the most effective dose/purity level, in order to seek a formulation which could be produced on a commercial scale. The results are measured by specific activity of alkaline phosphatase, calcium content, and histological examination. As noted previously, the specific activity of alkaline phosphatase is elevated during onset of bone formation and then declines. On the other hand, calcium content is directly proportional to the total amount of bone that is formed. The osteogenic activity due to osteogenic protein is represented by "bone forming units". For example, one bone forming unit represents the amount of protein that is needed for half maximal bone forming activity as compared to rat demineralized bone matrix as control and determined by calcium content of the implant on day 12.

## E. Results

[0115] Dose curves are constructed for bone inducing activity in vivo at each step of the purification scheme by assaying various concentrations of protein. FIGURE 11 shows representative dose curves in rats as determined by alkaline phosphatase. Similar results are obtained when represented as bone forming units. Approximately 10-12 µg of the TSK-fraction, 3-4 µg of heparin-Sepharose-II fraction, 0.4-0.5 µg of the C-18 column purified fraction, and 20-25 ng of gel eluted highly purified 30 kD protein is needed for unequivocal bone formation (half maximum activity). 20-25 ng of the substantially pure protein per 25 mg of implant is normally sufficient to produce endochondral bone. Thus, 1-2 ng osteogenic protein per mg of implant is a reasonable dosage, although higher dosages may be used. (See section IB5 on specific activity of osteogenic protein.)

[0116] OP1 expressed as set forth above (longer version), when assayed for activity histologically, induced cartilage and bone formation as evidenced by the presence of numerous chondrocytes in many areas of the implant and by the presence of osteoblasts surrounding vascular endothelium forming new matrix.

[0117] Deglycosylated xenogenic collagenous bone matrix (example: bovine) has been used instead of allogenic collagenous matrix to prepare osteogenic devices (see previous section) and bioassayed in rat for bone inducing activity in vivo. The results demonstrate that xenogenic collagenous bone matrix after chemical deglycosylation induces successful endochondral bone formation (FIGURE 19). As shown by specific activity of alkaline phosphatase, it is evident that the deglycosylated xenogenic matrix induced bone whereas untreated bovine matrix did not.

[0118] Histological evaluation of implants suggests that the deglycosylated bovine matrix not only has induced bone in a way comparable to the rat residue matrix but also has advanced the developmental stages that are involved in endochondral bone differentiation. Compared to rat residue as control, the HF treated bovine matrix contains extensively remodeled bone. Ossicles are formed that are already filled with bone marrow elements by 12 days. This profound action as elicited by deglycosylated bovine matrix in supporting bone induction is reproducible and is dose dependent with varying concentration of osteogenic protein.

## ANIMAL EFFICACY STUDIES

[0119] Substantially pure osteogenic protein from bovine bone (BOP), BOP-rich osteogenic fractions having the properties set forth above, and several recombinant proteins have been incorporated in matrices to produce osteogenic devices. The efficacy of bone-inducing potential of these devices was tested in cat and rabbit models, and found to be potent inducers of osteogenesis, ultimately resulting in formation of mineralized bone. The following sets forth guidelines as to how the osteogenic devices disclosed herein might be used in a clinical setting.

### A. Feline Model

[0120] The purpose of this study is to establish a large animal efficacy model for the testing of the osteogenic devices of the invention, and to characterize repair of massive bone defects and simulated fracture non-union encountered frequently in the practice of orthopedic surgery. The study is designed to evaluate whether implants of osteogenic protein with a carrier can enhance the regeneration of bone following injury and major reconstructive surgery by use of this large mammal model. The first step in this study design consists of the surgical preparation of a femoral osteotomy defect which, without further intervention, would consistently progress to non-union of the simulated fracture defect. The effects of implants of osteogenic devices into the created bone defects were evaluated by the following study protocol.



## A-1. Procedure

[0121] Sixteen adult cats weighing less than 10 lbs. undergo unilateral preparation of a 1 cm bone defect in the right femur through a lateral surgical approach. In other experiments, a 2 cm bone defect was created. The femur is immediately internally fixed by lateral placement of an 8-hole plate to preserve the exact dimensions of the defect. There are three different types of materials implanted in the surgically created feline femoral defects: group I (n = 3) is a control group which undergo the same plate fixation with implants of 4 M guanidine-HCl-treated (inactivated) feline demineralized bone matrix powder (Gu-HCl-DBM) (360 mg); group II (n = 3) is a positive control group implanted with biologically active feline demineralized bone matrix powder (DBM) (360 mg); and group III (n = 10) undergo a procedure identical to groups I-II, with the addition of osteogenic protein onto each of the Gu-HCl-DBM carrier samples. To summarize, the group III osteogenic protein-treated animals are implanted with exactly the same material as the group I animals, but with the singular addition of osteogenic protein.

[0122] All animals are allowed to ambulate ad libitum within their cages post-operatively. All cats are injected with tetracycline (25 mg/kg SQ each week for four weeks) for bone labelling. All but four group III animals are sacrificed four months after femoral osteotomy.

## A-2. Radiomorphometrics

[0123] In vivo radiomorphometric studies are carried out immediately post-op at 4, 8, 12 and 16 weeks by taking a standardized x-ray of the lightly anesthetized animal positioned in a cushioned x-ray jig designed to consistently produce a true antero-posterior view of the femur and the osteotomy site. All x-rays are taken in exactly the same fashion and in exactly the same position on each animal. Bone repair is calculated as a function of mineralization by means of random point analysis. A final specimen radiographic study of the excised bone is taken in two planes after sacrifice. X-ray results are shown in FIGURE 12, and displaced as percent of bone defect repair. To summarize, at 16 weeks, 60% of the group III femurs are united with average 86% bone defect regeneration. By contrast, the group I Gu-HCl-DMB negative-control implants exhibit no bone growth at four weeks, less than 10% at eight and 12 weeks, and 16% ( $\pm 10\%$ ) at 16 weeks with one of the five exhibiting a small amount of bridging bone. The group II DMB positive-control implants exhibited 18% ( $\pm 3\%$ ) repair at four weeks, 35% at eight weeks, 50% ( $\pm 10\%$ ) at twelve weeks and 70% ( $\pm 12\%$ ) by 16 weeks, a statistical difference of  $p < 0.01$  compared to osteogenic protein at every month. One of the three (33%) is united at 16 weeks.

## A-3. Biomechanics

[0124] Excised test and normal femurs are immediately studied by bone densitometry, wrapped in two layers of saline-soaked towels, placed in two sealed plastic bags, and stored at  $-20^{\circ}\text{C}$  until further study. Bone repair strength, load to failure, and work to failure are tested by loading to failure on a specially designed steel 4-point bending jig attached to an Instron testing machine to quantitate bone strength, stiffness, energy absorbed and deformation to failure. The study of test femurs and normal femurs yield the bone strength (load) in pounds and work to failure in joules. Normal femurs exhibit a strength of 96 ( $\pm 12$ ) pounds. osteogenic protein-implanted femurs exhibited 35 ( $\pm 4$ ) pounds, but when corrected for surface area at the site of fracture (due to the "hourglass" shape of the bone defect repair) this correlated closely with normal bone strength. Only one demineralized bone specimen was available for testing with a strength of 25 pounds, but, again, the strength correlated closely with normal bone when corrected for fracture surface area.

## A-4. Histomorphometry/Histology

[0125] Following biomechanical testing the bones are immediately sliced into two longitudinal sections at the defect site, weighed, and the volume measured. One-half is fixed for standard calcified bone histomorphometrics with fluorescent stain incorporation evaluation, and one-half is fixed for decalcified hematoxylin/eosin stain histology preparation.

## A-5. Biochemistry

[0126] Selected specimens from the bone repair site (n=6) are homogenized in cold 0.15 M NaCl, 3 mM  $\text{NaHCO}_3$ , pH 9.0 by a Spex freezer mill. The alkaline phosphatase activity of the supernatant and total calcium content of the acid soluble fraction of sediment are then determined.

## A-6. Histopathology

**[0127]** The final autopsy reports reveal no unusual or pathologic findings noted at necropsy of any of the animals studied. Portion of all major organs are preserved for further study. A histopathological evaluation is performed on samples of the following organs: heart, lung, liver, both kidneys, spleen, both adrenals, lymph nodes, left and right quadriceps muscles at mid-femur (adjacent to defect site in experimental femur). No unusual or pathological lesions are seen in any of the tissues. Mild lesions seen in the quadriceps muscles are compatible with healing responses to the surgical manipulation at the defect site. Pulmonary edema is attributable to the euthanasia procedure. There is no evidence of any general systemic effects or any effects on the specific organs examined.

## A-7. Feline Study Summary

**[0128]** The 1 cm and 2 cm femoral defect cat studies demonstrate that devices comprising a matrix containing disposed osteogenic protein can: (1) repair a weight-bearing bone defect in a large animal; (2) consistently induces bone formation shortly following (less than two weeks) implantation; and (3) induce bone by endochondral ossification, with a strength equal to normal bone, on a volume for volume basis. Furthermore, all animals remained healthy during the study and showed no evidence of clinical or histological laboratory reaction to the implanted device. In this bone defect model, there was little or no healing at control bone implant sites. The results provide evidence for the successful use of osteogenic devices to repair large, non-union bone defects.

B. Rabbit Model:

## B1. Procedure and Results

**[0129]** The purpose of this study is to establish a model in which there is minimal or no bone growth in the control animals, so that when bone induction is tested, only a strongly inductive substance will yield a positive result. Defects of 1.5 cm are created in the ulnae of rabbits with implantation of osteogenic devices or no implant.

**[0130]** Eight mature (greater than 10 lbs) New Zealand White rabbits with epiphyseal closure documented by X-ray were studied. Of these eight animals (one animal each was sacrificed at one and two weeks), 11 ulnae defects are followed for the full course of the eight week study. In all cases (n = 7) following osteo-periosteal bone resection, the no implant animals establish no radiographic union by eight weeks. All no implant animals develop a thin "shell" of bone growing from surrounding bone present at four weeks and, to a slightly greater degree, by eight weeks. In all cases (n = 4), radiographic union with marked bone induction is established in the osteogenic protein-implanted animals by eight weeks. As opposed to the no implant repairs, this bone repair is in the site of the removed bone.

**[0131]** Radiomorphometric analysis reveal 90% osteogenic protein-implant bone repair and 18% no-implant bone repair at sacrifice at eight weeks. At autopsy, the osteogenic protein bone appears normal, while "no implant" bone sites have only a soft fibrous tissue with no evidence of cartilage or bone repair in the defect site.

## B-2. Allograft Device

**[0132]** In another experiment, the marrow cavity of the 1.5 cm ulnar defect is packed with activated osteogenic protein rabbit bone powder and the bones are allografted in an intercalary fashion. The two control ulnae are not healed by eight weeks and reveal the classic "ivory" appearance. In distinct contrast, the osteogenic protein-treated implants "disappear" radiographically by four weeks with the start of remineralization by six to eight weeks. These allografts heal at each end with mild proliferative bone formation by eight weeks.

**[0133]** This type of device serves to accelerate allograft repair.

## B-3. Summary

**[0134]** These studies of 1.5 cm osteo-periosteal defects in the ulnae of mature rabbits show that: (1) it is a suitable model for the study of bone growth; (2) "no implant" or Gu-HCl negative control implants yield a small amount of periosteal-type bone, but not medullary or cortical bone growth; (3) osteogenic protein-implanted rabbits exhibited proliferative bone growth in a fashion highly different from the control groups; (4) initial studies show that the bones exhibit 50% of normal bone strength (100% of normal correlated vol:vol) at only eight weeks after creation of the surgical defect; and (5) osteogenic protein-allograft studies reveal a marked effect upon both the allograft and bone healing.

**[0135]** The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and

all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

[0136] The invention relates to an osteogenic device for implantation in a mammal, said device comprising: a bio-compatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and substantially pure osteogenic protein capable of inducing endochondral bone formation in said mammal disposed in said matrix and accessible to said cells.

[0137] In another aspect, the invention relates to substantially pure osteogenic protein capable of inducing endochondral bone formation in a mammal when disposed within a matrix implanted in said mammal.

[0138] Preferably, in the device said matrix comprises close-packed particulate matter having a particle size within the range of 70-420  $\mu\text{m}$ . Said matrix may comprise demineralized, protein-extracted, particulate, allogenic bone.

[0139] Preferably, said matrix comprises collagen, hydroxyapatite, tricalcium phosphate, polymers comprising lactic acid monomer units, polymers comprising glycolic acid monomer units, demineralized, guanidine-extracted allogenic bone, or a mixture thereof.

[0140] The device may be shaped to span a non-union fracture in said mammal.

[0141] The device may be disposed within the marrow cavity of allogenic bone.

[0142] The device may comprise a matrix which comprises demineralized, protein extracted, particulate, deglycosylated xenogenic bone.

[0143] The matrix may be treated with a protease.

[0144] The osteogenic protein may be unglycosylated and/or may have an apparent molecular weight of about 27 kD when oxidized as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

[0145] The osteogenic protein may be glycosylated and/or may have an apparent molecular weight of about 30 kD when oxidized as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

[0146] The osteogenic protein may comprise a pair of polypeptide chains. In such embodiments, one chain of said pair of polypeptide chains may have an apparent molecular weight of about 14 kD and the other may have an apparent molecular weight of about 16 kD, both as determined after reduction by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis. Alternatively, one chain of said pair of polypeptide chains may have an apparent molecular weight of about 16 kD and the other may have an apparent molecular weight of about 18 kD, both as determined after reduction by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

[0147] The osteogenic protein may have the approximate amino acid composition set forth below:

Amino acid residue	Rel. no. res./molec.	Amino acid residue	Rel. no. res./molec.
Aspartic acid/Asparagine	22	Tyrosine	11
Glutamic acid/ Glutamine	24	Valine	14
		Methionine	3
		Cysteine	16
Serine	24	Isoleucine	15
Glycine	29	Leucine	15
Histidine	5	Proline	14
Arginine	13	Phenylalanine	7
Threonine	11	Tryptophan	ND
Alanine	18		
Lysine	12		

[0148] The osteogenic protein may comprise the amino acid sequence: VPKPCCAPT.

[0149] Preferably, the half maximum bone inducing activity of said protein is 0.8 to 1.0 ng per mg of said matrix.

[0150] The invention also relates to a method of inducing local cartilage or bone formation in a mammal comprising the step of implanting the device of the invention in said mammal at a locus accessible to migratory progenitor cells of said mammal.

[0151] Also contemplated by the invention is a method of inducing endochondral bone formation in a mammal comprising the step of implanting the device of the invention in said mammal at a locus accessible to migratory progenitor cells of said mammal.

[0152] The invention also contemplates a method of inducing endochondral bone formation in a non-union fracture in a mammal comprising the step of implanting in the fracture in said mammal the device of the invention.

[0153] The protein may comprise the sequence:



10 or

--5  
HQRQA  
15                   1                   10                   20                   30                   40  
OP1           CKKHELIVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS  
50                   60                   70  
          YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA  
80                   90                   100  
20           ISVLYFDDSSNVILKKYRNMVVVRACGCH

**[0158]** The device may comprise a matrix having demineralized, protein extracted, particulate xenogenic bone treated with HE.

## Claims

1. Use of a composition consisting essentially of a single species of osteogenic protein as active osteogenic ingredient, said protein comprising an unpaired polypeptide chain capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation.
2. Use of a composition consisting essentially of a single species of osteogenic protein as active osteogenic ingredient, which osteogenic protein does not comprise a pair of polypeptide chains and is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation.
3. Osteogenic protein comprising an unpaired polypeptide chain capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, the protein being in unglycosylated form.
4. Osteogenic protein comprising a polypeptide chain capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, which protein does not comprise a pair of polypeptide chains and is in unglycosylated form.
5. A process for the production of a polypeptide chain for use in the preparation of an active osteogenic protein, comprising the steps of: (a) providing genetic material encoding the osteogenic protein; (b) introducing the genetic material into a prokaryotic host cell; (c) expressing the genetic material in the host cell and (d) refolding the expressed protein by oxidation.
6. The process of claim 5 wherein the protein comprises a TGF-beta-like domain comprising seven cysteines.
7. A polypeptide chain producible by the process of claim 5 or claim 6.
8. The use of claim 1 or claim 2, protein of claim 3 or claim 4, process of claim 5 or claim 6 or polypeptide of claim 7, wherein the protein:

(a) comprises the amino acid sequence VPKPCCAPT;

(b) comprises the amino acid sequence

```

1      10      20      30      40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
5      50      60      70
YMNATN--H-AIVQTLVHF'INPET-VPKPCCAPTQLNA
80      90      100
ISVLYFDDSSNVILKKYRNMVVRACGCH; or

```

(c) comprises the amino acid sequence

```

1      10      20      30      40      -5
HQRQA
CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
15      50      60      70
YMNATN--H-AIVQTLVHF'INPET-VPKPCCAPTQLNA
20      80      90      100
ISVLYFDDSSNVILKKYRNMVVRACGCH; or

```

(d) comprises the amino acid sequence

```

1      10      20      30      40
CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
30      50      60      70
HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
80      90      100
ISMLYDENEKVVLKKNYQDMVVEGCGCR; or

```

(e) comprises the amino acid sequence

```

1      10      20      30      40
CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPFLAD
40      50      60      70
HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
80      90      100
ISMLYLDEYDKVVLKKNYQEMVVEGCGCR; or

```

(f) comprises the amino acid sequence

```

1      10      20      30      40
CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMK
50      50      60      70
SLKPSN--H-ATIQSIVRAVGVPVGIPEPCCVPEKMSS
55      80      90      100
LSILFFDENKNVVLKVYPNMTVESACR; or

```

(g) comprises that sequence of amino acids encoded by a DNA sequence retrievable by hybridization with

the probe of Figure 13.

9. The use of claim 1 or claim 2, protein of claim 3 or claim 4, process of claim 5 or claim 6, polypeptide of claim 7 or use, protein, process or polypeptide of claim 8, wherein the protein:

(a) has an apparent molecular weight of about 30 kD in the glycosylated native form as determined by SDS-PAGE; or  
 (b) has an apparent molecular weight of about 27 kD in deglycosylated form as determined by SDS-PAGE; or  
 (c) comprises two polypeptide chains which have an apparent molecular weight of about 16 kD and 18 kD in glycosylated form;  
 (d) comprises two polypeptide chains which have an apparent molecular weight of about 14 kD to 16 kD in unglycosylated form.

10. The process of any one of claims 5-9 wherein the host cell is an E. coli host cell.

11. A process for producing an osteogenic device comprising disposing a protein as defined in any one of the preceding claims in a matrix.

12. The process of claim 11 wherein the device is for implantation in a mammal and comprises:

(a) a biocompatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal, and  
 (b) the protein disposed in said matrix and accessible to said cells.

13. The process of claim 12 wherein said matrix comprises close-packed particulate matter having a particle size within the range of 70 to 420  $\mu\text{m}$ .

14. The process of any one of claims 11-13 wherein said matrix comprises:

(a) allogenic bone, e.g. demineralized, protein extracted, particulate, allogenic bone, (b) demineralized, protein extracted, particulate, deglycosylated xenogenic bone (which is e.g. treated with a protease), (c) demineralized, protein extracted, particulate xenogenic bone treated with HF, (d) materials selected from collagen, hydroxyapatite, calcium phosphates (e.g. tricalcium phosphate) and polymers comprising glycolic acid and/or lactic acid monomers, (e) a shape-retaining solid of loosely adhered particulate material e.g. collagen, (f) a porous solid, (g) masticated tissue, e.g. muscle or (h) the marrow cavity of allogenic bone.

15. The process of any one of claims 11-14 wherein the device is for use in therapy, e.g. for inducing local cartilage and/or endochondral bone formation in a mammal by implanting the device in a mammal at a locus accessible to migratory progenitor cells for periodontal treatment, cartilage repair, accelerating allograft repair and for the treatment of osteoarthritis or to correct non-union fractures, acquired or congenital craniofacial and other skeletal or dental anomalies.

FIG. 1A-1  
 10 20 30 40 50 60 70  
 GGAGGTATAGGAGCTCTCTTCGATTTTAGCAACCAGGAGTCCGAAGATCTAAGGAGAGCTGGGGGTTTGACTCC  
 SacI BglII  
 85 95 105 115 125 135 145  
 GAGAGCTCGAGAGTCCCCAAGACCTGGTCTTGACTCAGAGTTAGACTCCACTCAGAGGCTGACTGTCTCCAGG  
 SacI PflMI  
 XhoI TthlIII  
 160 170 180 190 200 210 220  
 GTCTACACCTCTAAGGCGACACTGGGCTCAAGCAGACTGCCGTTTCTATATGGGATGAGCCTTTCACAGGGCAG  
 235 245 255 265 275 285 295  
 CCAGTTGGGATGGGTTGAGGTTTGGCTGTAGACATCAGAAACCCCAAGTCAAAATGCCGCTTCAACCAGTAGAAAAATT  
 310 320 330 340 350 360 370  
 CACCAGCCCGCAGAGCTAAGGTTGGGTGGACATTAGGGTTGGTTGATCCAGGAGCTCAACAGTGTCTCTGTAGGCC  
 SacI  
 385 395 405 415 425 435 445  
 CCAGCTCCTTCTGCCCCACCCACCACATCTTCAGTGTCTTCCCTCTCAAGGCCACAGCTGTAGTTGGCCAGGGGG  
 PvuII BglI  
 460 470 480 490 500 510 520  
 GCTTCATTATTTTGTCTCCTGGGCAGTAGGAGGAAGAGAATGAATGTCTCTCCATGGGTCTTTCTTAGGAATGT  
 NcoI  
 535 545 555 565 575 585 595  
 GGGAACCTTTTCCAGAAAGTCTCTATGTCTTTTAGTTTGTGTTGGGTCACTTGCCCTTCCCTGAACCACCTTCCCTGAC  
 610 620 630 640 650 660 670  
 TCCTGGACAGGATGTGCACCTGATGAGCTTAGCTTTGGGGA'TCTAATAGTGACTTTACAAAGCCTCTTTGAGAAAG  
 ApaLI EspI  
 685 695 705 715 725 735 745  
 TGACAT'TGGAAACCAAGGCTTGAGCAGACACAACAAGAT'TGCAGGGAGGGGCAT'TGCAGGTGGAGGAACCGGCAC  
 BspMI -  
 760 770 780 790 800 810 820  
 ATGCAAGAGCCCTGCGTGGGAGTGAGCTTGGTGT'TGGTCAATCAGTT'GTCAGAGCACACCGGGGCCCTTGTACAGCA  
 ApaI  
 EcoO



FIG. 1A-2

835 845 855 865 875 885 895  
 GGCACAGCCTGGGGCCTGCTCTGAGTA'TGACACAGAGAGCCCCCTGGGAAGT'TGTAGGTGGAGGAAAGACAGGT'CATGA  
 910 920 930 940 950 960 970  
 CTAGGAAAAAAGCAATCCCTCTGTTGTGGGGTGAAGAAAGTTGCAGTGTGTGAGAGAGAGACAGACAGAC  
 985 995 1005 1015 1025 1035 1045  
 AGACAGACACTTCTCAATGTTTACAAGTGCTCAGGCCCTGACCCCGAATGCTTCCAAATTTACGTAGTTCTTGGA  
 EcoO BsmI+ SnaBI  
 1060 1070 1080 1090 1100 1110 1120  
 ACCCCCTGTATCATTTTCACTACTCAAAGAAACCTCGGGAGTGT'TTCTTCTGAAAGGTCAATCAGGTTT'TGACTC  
 1135 1145 1155 1165 1175 1185 1195  
 TCTGCTGTCTCATTTTCTTCTGTGGTGGTGATGGTTGCTTGTCCAGGGCCCTGTCCCGCATCCTCTTGGCCC  
 EcoO  
 1210 1220 1230 1240 1250 1260 1270  
 CTGCAGAGGGATGAGTGTGTGGGGCCTCACGAGTTGAGGTTGTTCATAAGCAGATCTCTTTGAGCAGGGCGCCT  
 PstI EcoO BglII NarI Ps  
 1285 1295 1305 1315 1325 1335 1345  
 GCAGTGGCCCTTGTGTGAGGCTGGAGGGGTTTTCGATTCCCTTATGGAATCCAGGCAGATGTAGCATTTAAACAACA  
 tI DraI  
 1360 1370 1380 1390 1400 1410 1420  
 CACGTGTATAAAAGAAACCAGTGTCCGCAGAAAGTTCCAGAAAGTATTATGGGATAAGACTACATGAGAGAGGAA  
 1435 1445 1455 1465 1475 1485 1495  
 TGGGGCAATTGGCACCTCCCTTAGTAGGGCCTTTTGCTGGGGGTAGAAATGAGTTTAAAGGCAGGTTAGACCCCTCGA  
 EcoO BspMI-  
 1510 1520 1530 1540 1550 1560 1570  
 ACTGGCTTTTGAATCGGGAATTTACCCCCCAGCCGTTCTGTGCTTCATTGCTGTTCACATCACTGCCCTAAGATG  
 1585 1595 1605 1615 1625 1635 1645  
 GAGGAACTTTTGATGTGTGTGTTCTTTCTCCTCACTGGGCTCTGCTTCTTCACTTCCCTGTCAATGCAGAGAA  
 1660 1670 1680 1690 1700 1710 1720  
 CAGCAGCAGGCCACAGAGGCCTTGTAAAGACAGCAGCTGTATGTACGCTTCCGAGACCTGGGCTGGCAGG  
 StuI BspMI  
 1735 1745 1755 1765 1775 1785 1795  
 TAAGGGGCTGGCTGGGTCTGTCTTGGGTGTGGGCCCTCTGGCGTGGGCTCCACAGGCAGCGGGTGTGTGCTCA  
 ApaI  
 EcoO

FIG. 1A-3

FIG. 1A-4

2710 2720 2730 2740 2750 2760 2770  
 ATTGCCATGTCATGACTTTTGGGGGCCCCCTTGGCGCGTTAAATAAAATCAAAAATTGTACTTTATGACTGGTTT  
 ApaI  
 2785 2795 2805 2815 2825 2835 2845  
 GGTATAAGAGGAGTATAATCTTCGACCCCTGGAGTTCAATTATTTCTCCTAATTTTAAAGTAACTAAAAGTTGT  
 DraI  
 2860 2870 2880 2890 2900 2910 2920  
 ATGGGCTCCTTTGAGGATGCTTGTAGTATTGTGGTGCTGGTTACGGTGCCTAAGAGCACTGGGCCCTGCTTCA  
 ApaI  
 2935 2945 2955 2965 2975 2985 2995  
 TTTTCCAGTAGAGGAAACAGGTAAACAGATGAGAAAATTTTCAGTGAGGGGCACAGTGATCAGAAAGCGGGCCAGCAG  
 3010 3020 3030 3040 3050 3060 3070  
 GATAATGGGATGGAGAGATGAGTGGGGACCCCATGGGCCATTTCAAAGTTAAATTTTCAGTCGGGTCAACAGGAAGAT  
 BstEII  
 3085 3095 3105 3115 3125 3135 3145  
 TCCATGTGATAATGAGATTAAACGTGCCCCAGTCACGGCGACACTCAGTAGTGTTATTCCTGCTCTGCCAACAGCA  
 3160 3170 3180 3190 3200 3210 3220  
 ACCATAGTTGATAAGAGCTGTTAGGGATTTTGTCCCTTTTGCTTAGAATCCAAGGTTCAAGGACCTTGGTTATGTA  
 EcoO  
 3235 3245 3255 3265 3275 3285 3295  
 GCTCCCTGTCAATGACATCATCTGAGCCCTTTCCTGCCTACTGATCATCCACCCCTGCCCTTGAATGCTTCTAGTGAC  
 BsmI+  
 3310 3320 3330 3340 3350 3360 3370  
 AGAGAGCTCACTACCAGGACTACTCCCTCCTTTTCATTATAGTAATCTGCCTCCTTCTTTCTTGTCCCTGTCCTGT  
 SacI  
 3385 3395 3405 3415 3425 3435 3445  
 GTGTTAAGTCCCTGGAGAAAAATCTCATCTATCCCTTTTCAATTTTGATTTCTGCTCTTTGAGGGCAGGGGTTTTTGT  
 3460 3470 3480 3490 3500 3510 3520  
 CTTTGTGTTTTTTTAAAGTGTGGTTTTTCCAAAAGCCCTTGCTCCCCCTCCTCAATTGAAACTTCAAAAGCCCTCAT  
 3535 3545 3555 3565 3575 3585 3595  
 TGGGATTGAAGTCCCTTAGGCTGGAAACAGAGATCCTCCCCAACCTGTTCCCTGGCCCTGGATGTGCTGTGCTG  
 EcoOMstII

FIG. 1A-5

3610 3620 3630 3640 3650 3660 3670  
 T'GCCAGTAT'CCCCCTGGAAGGTGCCAGGCATGTCTCCCCGGCTGCCAGGGGACACATCTCTATCTCTTCTCCCAACCC  
 3685 3695 3705 3715 3725 3735 3745  
 CTGCCCTTCA'TGGCCCATGTGAACACAGAGTGCCCATCGCCCTGTGTGCACCTACTTCCATCAGTATTTCCACCAGAGAT  
 BglI NcoI ApaLI BglI  
 3760 3770 3780 3790 3800 3810 3820  
 CTGCAGGATCAAAAGTGAATTTCTCCAGGGATTTGTGAAATGATGCGATTGTGGTCATGTTTAAAGGGGGCAACTGT  
 I EcoRI DraI  
 PstI  
 3835 3845 3855 3865 3875 3885 3895  
 CTTC'TAGAGAGT'CCCTGATGAAATGCTTCCAGAGGAAATGAGCTGATGGCTGGAAATTTGCTTTAAAAATCATTTCAAG  
 XbaI DraI  
 3910 3920 3930 3940 3950 3960 3970  
 GTGGAGCAGTGGGGAAGGTATGGATGTGTAAGAGTTTGAAATTTGTCCATCATATAAAATGTGTAATAAGCATGCT  
 BspMI - SphI  
 3985 3995 4005 4015 4025 4035 4045  
 GGCCTATGTCAGCAGTCAACAGCCCTGGAGGTGGTAACAGAGTGCCAGTCACTGATGCTCAAGCCTGGCACCTACAG  
 4060 4070 4080 4090 4100 4110 4120  
 T'TGCT'GGAAACCCAGAAAGTTTCAACGTTGAAACAACACAGGACAGTGGAATCTCTGGCCCTGTCTTTGAACACACGTGGC  
 4135 4145 4155 4165 4175 4185 4195  
 AGATCTGCTAACACTGATCTTGGTTGGCTGCCGTCAAGCTTAGGTTGAGTGGCGGTCTTCCCTTAGTTTGGCTTAGT  
 BglII  
 4210 4220 4230 4240 4250 4260 4270  
 CCCCCGTATTCCCTATTGTC'TTACCCTCGGTCTATT'TTGGCTTATCAGTGGACCTCACCAGGCACTCATAGGCATT  
 4285 4295 4305 4315 4325 4335 4345  
 GAGTC'TATGT'GTCCCTGTCCACATCCCTCTGTAAAGGTGCAGAGAAAGTCCATGAGCAAGATGGAGCACCTTCTTAGTG  
 4360 4370 4380 4390 4400 4410 4420  
 GGTCCAAGTCAGGGACACTAT'TCAGCAA'TCTACAGTGCACAGGGCAGTTTCCCCAACACAGAGAATTTACCTGGTCTG  
 ApaLI  
 4435 4445 4455 4465 4475 4485 4495  
 AATGTGGATCTGGCCCCCTTCCTTCCCCCACTGTATATAATGTGAAAAACCTCTATGCTTTGT'TCCCCCTTGTCTGCAAA  
 4510 4520 4530 4540 4550 4560 4570  
 ACAGGGATAATCCCAGAACTGAGTTGTCCATGTAAAGTGCTTAGAACACAGGGAGTGCTTTGGCTTGGGGAGTGTCAAC  
 BS

## FIG. 1A-6

4585 4595 4605 4615 4625 4635 4645  
 CTGCAGTCATTCATTATGCCCCAGACAGGATGTTCTTTATAGAAACGTGGAGGCCAGTTAGAACGACTCACCGCT  
 pMI+  
 Pst I  
 4660 4670 4680 4690 4700 4710 4720  
 TCTCACCACTGCCCATGTTTGGTGTGTGTTTCAGGTCCCACTTCATCAACCCCGGAACGGTGCCCAAGCCCTGCT  
 PflMI  
 4735 4745 4755 4765 4775 4785 4795  
 GTGGGCCCCACGCAGCTCAATGCCATCTCCGTCCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACA  
 4810 4820 4830 4840  
 GAAACATGGTGTCCGGCCCTGTGGCTGCCCACTAGCTCCTCCGA

FIG. 1B

```

CONSENSUS PROBE      20      30      40      50      60      70
GATCCTAATGGGCTGTACGTGGACTTCCAGCGGACGCTGGGCTGGGACGACTGGATCATCGCCCCCGTCG
** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** ** **
TGTAAGAACGACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTGAAG
OP4  28      38      48      58      68      78      88

      80      90      100     110     120     130     140
ACTTCGACGCCCTACTACTGCTCCGGAGCCTGCCAGTTCCCCCTCTGCGGATCAGTTCAACAGCACCAACCA
** ** ***** ** ** ***** ** ** *****
GCTACGCGCGCTACTACTGTGAGGGGAGTGTGCCTTCCCTCTGAACTCCTACATGAACGCCACCAACCA
98      108     118     128     138     148     158

      150     160     170     180     190     200     210
CGCCGTGGTGCAGACCCCTGGTGAACAACATGAACCCCGGCAAGGTACCCCAAGCCCTGCTGCGTGCCCCACC
**** ***** **** ** ***** ** ** *****
CGCCATCGTGCAGACGCTGGTCCACTTCATCAACCCCGGAAACGGTGTCCCAAGCCCTGCTGTGCGCCACG
168     178     188     198     208     218     228

      220     230     240     250     260     270     280
GAGCTGTCCGCCCATCAGCATGCTGTACCTGGACGAGAAATTCACCCGTGGTGGTGAAGAACTACCAGGAGA
**** ***** ** ** ** ** ** ***** **
CAGCTCAATGCCCATCTCCGTCCCTACTTCGATGACAGCTCCAACGTCACTCCCTGAAGAAATACAGAAACA
238     248     258     268     278     288     298

      290     300     310
TGACCGTGGTGGGCTGCGGCTGCCGCTAACTGCA
** ** ***** **
TGGTGTCGCGGCCTGTGGCTGCCACTAGCTCCT
308     318     328

```




FIG. 2A






FIG. 2B



BUFFER: 4M GUANIDINE HCl, 50mM TRIS, PH 7.0

FIG. 2C



UB: 6MUREA 50mMTRIS 0.1MNaCl PH 7.0

B<sub>1</sub>: 6MUREA 50mMTRIS 0.15MNaCl PH 7.0

B<sub>2</sub>: 6MUREA 50mMTRIS 0.5MNaCl PH 7.0

FIG. 2D

FIG. 3A FIG. 3B




FIG. 4A FIG. 4B



FIG. 5A



FIG. 5B






FIG. 6 A FIG. 6 B FIG. 6 C FIG. 6 D FIG. 6 E




FIG. 15



— 18K SUBUNIT  
— 16K SUBUNIT




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

## FIG. 13

10 20 30 40 50  
GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGA  
D P N G L Y V D F Q R D V G W D D

60 70 80 90 100  
CTGGATCATCGCCCCCGTTCGACTTCGACGCCTACTACTGCTCCGGAGCCT  
W I I A P V D F D A Y Y C S G A

110 120 130 140 150  
GCCAGTTCCCCTCTGCGGATCACTTCAACAGCACCAACCACGCCGTGGTG  
C Q F P S A D H F N S T N H A V V

160 170 180 190 200  
CAGACCCTGGTGAACAACATGAACCCCGGCAAGGTACCCAAGCCCTGCTG  
Q T L V N N M N P G K V P K P C C

210 220 230 240 250  
CGTGCCCAACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATT  
V P T E L S A I S M L Y L D E N

260 270 280 290 300  
CCACCGTGGTGCTGAAGAACTACCAGGAGATGACCGTGGTGGGCTGCGGC  
S T V V L K N Y Q E M T V V G C G

310  
TGCCGCTAACTGCAG  
C R \*

SDS GEL ELUTION OF OSTEOGENIC ACTIVITY  
CALCIUM CONTENT (ug/mg tissue)




FIG. 14




FIG. 18




FIG. 16A




FIG. 16B






FIG. 17A




FIG. 17 B



FIG. 17C




FIG. 19A




FIG. 19B



## EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
08.01.2003 Bulletin 2003/02

(51) Int Cl.7: **C12N 15/12**, C07K 14/51,  
A61K 38/18, A61L 27/22,  
A61L 27/54

(43) Date of publication A2:  
24.07.2002 Bulletin 2002/30

(21) Application number: **01201546.7**

(22) Date of filing: **07.04.1989**

(84) Designated Contracting States:  
**AT BE CH DE FR GB IT LI LU NL SE**

(30) Priority: **08.04.1988 US 179406**  
**15.08.1988 US 232630**  
**23.02.1989 US 315342**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**95201872.9 / 0 714 665**  
**89904986.0 / 0 362 367**

(71) Applicant: **STRYKER CORPORATION**  
**Kalamazoo, Michigan 49003-4085 (US)**

(72) Inventors:

- **Kuberasampath, Thangavel**  
**Holliston, MA 01746 (US)**
- **Oppermann, Hermann**  
**Medway, Massachusetts 02053 (US)**
- **Rueger, David C.**  
**West Roxbury, Massachusetts 02132 (US)**
- **Ozkaynak, Engin**  
**Milford, Massachusetts 01757 (US)**

(74) Representative: **Hutchins, Michael Richard et al**  
**FRY HEATH & SPENCE LLP**  
**The Old College**  
**53 High Street**  
**Horley Surrey RH6 7BN (GB)**

(54) **Osteogenic devices**

(57) Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino

acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, and 3) methods of producing osteogenic proteins using recombinant DNA technology.

FIG. 1A-1

```

10      20      30      40      50      60      70
GGAGGTATAGGAGCTCTCTCGATTTTAGCAAACAGGAGTCCGAAGATCTAAGGAGAGCTGGGGTTTGACTCC
      SacI
85      95      105     115     125     135     145
GAGAGCTCGAGCAGTCCCCAAGACCTGGTCTTGACTCAGGAGTTAGACTCCACTCAGAGGCTGACTGTCTCCAGG
      SacI      PflMI
160     170     180     190     200     210     220
GTCTACACCTCTAAGGGCGACACTGGGCTCAAGCAGACTGCCGTTTCTATATGGGATGAGCCTTCACAGGGCAG
235     245     255     265     275     285     295
CCAGTTGGGATGGGTTGAGGTTTGGCTGTAGACATCAGAAACCAAGTCAAATGCCGTTCAACCAGTAGAAAATT
310     320     330     340     350     360     370
CACCAGCCCCAGAGCTAAGGTTGGGTGGACATTAGGGTTGGTTGATCCAGGAGCTCAACAGTGTCTCTGAGCC
      SacI
385     395     405     415     425     435     445
CCAGCTCCTTCTGCCCCACCCACCATCTTCAGTGTGCTTCTCTCAAGGCCACAGCTGTAGTTGGCCAGGGGG
      PvuII      BglI
460     470     480     490     500     510     520
GCTTCATTATTTTGGCTCCTGGGAGTGGGAGGAAGAGAATGAATGTCTCTCCATGGGTCTTTCTTAGGAATGT
      NcoI
535     545     555     565     575     585     595
GGGAACCTTTTCCAGAAGTCTCTATGTCTTTAGTTTGTGTTGGGTCACTTGCCCTTCTCTGAACCACTTCCTGAC
610     620     630     640     650     660     670
TCCTGGACAGGATGTGCACTGATGAGCTTAGCTTTGGGGATCTAATAGTGACTTTACAAAGCCTCTTTGAGAAGG
      ApaLI      EspI
685     695     705     715     725     735     745
TGACATTGGAACCAAGGCTTGAGCAGACACAACAAAGATTGCAGGGAGGGGCAATTGCAGGTGGAGGAAACGGCAC
      BspMI-
760     770     780     790     800     810     820
ATGCAAGAGCCCTGCGTGGGAGTGAGCTTGGTGTGGTCAATCAGTTGTGAGAGCACACCGGGCCCTGTGAGCA
      ApaI
      EcoO

```

FIG. 1A-2

[illegible]

FIG. 1A-3

[illegible]

FIG. 1A-4

**1A-4** 2710 2720 2730 2740 2750 2760 2770  
 ATTGCTATGTCAGTACTTTGGGGGCCCTCTGGCGCTAAAAAAAATCAAAAATGTGACTTTATGACTGGTTT  
 ApeI  
 EcoO  
 2785 2795 2805 2815 2825 2835 2845  
 GGTATAAAGAGAGCTATAATCTTCAGCCCTGGAGTTCATTATTCTTCTCTAAATTTATAAGTACTAAAGATGTT  
 DnaI  
 2860 2870 2880 2890 2900 2910 2920  
 ATGGGCTCCTTTGAGAGTCTTTGTATGTTCTTGCTTGCTTGCTACGTGCTCTAAGACACTAGGCCCTGCTCTCA  
 PvuII  
 EcoO  
 2935 2945 2955 2965 2975 2985 2995  
 TTTTCCAGTACAGAAAGACCTAAACAGTACGAAATTTTCAGTACGGGCGACAGTGTACAGAGCGGCGACGAC  
 3010 3020 3030 3040 3050 3060 3070  
 GATATAATGGGATCGAGACATGCTGGGACCACTGGGCCATTCAAGTAAATTTTCAAGTCGGGTACCAAGAACT  
 BstEII  
 3085 3095 3105 3115 3125 3135 3145  
 TCCGATATGATAATGAGATTAATCGTCCCACTACGGGACCACTACGATGAGTGTATTCTCTGCTCTCCGACAGCA  
 3160 3170 3180 3190 3200 3210 3220  
 ACCATAGTGTACAAGACGTTTAGGATTTTCTTCTCTTCTTCACTAGCAATCAAGGTTCAAGACCTTGTTATGTA  
 3235 3245 3255 3265 3275 3285 3295  
 GCTCCCTGTATAGCAATCATCTGAGCCTTTCTGCTGCTCATGATCAACACCTCGCTCGATAGTGCTTCTAGTCAC  
 3310 3320 3330 3340 3350 3360 3370  
 AGAGGCTCATCTACAGGACTCATCCCTCTTTCAATTTATGATTAATGCTCTGCTCTTTCTTCTGCTCCGCTGCTGT  
 BseI  
 3385 3395 3405 3415 3425 3435 3445  
 CTTTATGCTCCGTCGGAGAAAGCTCATCTCTCTCTCTTGTGATCTGCTCTCTTGGGAGGACGAGTTTGTGTT  
 3460 3470 3480 3490 3500 3510 3520  
 TTTCTGTGTTTGTTTTAAATGTTGTCTTTCCAAAGCCCTGCTTCCCTCTCTAAATGAAATCTCAAGAGCCCTCAT  
 EcoS  
 3535 3545 3555 3565 3575 3585 3595  
 TGGGATTTGATGATGCTGCTGGAAGACGAAGATGCTTCCCAACCTCTTCTCTGGCTGTGATGCTGTGCTGCTG  
 EcoWetII

FIG. 1A-5

[illegible]

FIG. 1A-6

4585      4595      4605      4615      4625      4635      4645  
 CTGCAGTCATTTCATTATGCCCAGACAGGATGTTTCTTTATAGAAACGTGGAGGCCAGTTAGAACGACTCACCCTGCT  
 PMI+  
 PstI  
 4660      4670      4680      4690      4700      4710      4720  
 TCTCACCAGTGCCTCATGTTTGGTGTGTGTTTCAGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCT  
 PflMI  
 4735      4745      4755      4765      4775      4785      4795  
 GTGCGCCACGCAGCTCAATGCCATCTCCGTCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACA  
 4810      4820      4830      4840  
 GAAACATGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCCTCCGA

FIG. 1B

CONSENSUS PROBE      20      30      40      50      60      70  
 GATCCTAATGGGCTGTACGTGGACTTCCAGCGGACGTGGGCTGGGACGACTGGATCATCGCCCCCGTGG  
 \*\*      \* \* \* \* \*  
 TGTAAGAAGCAGGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTGAAG  
 OP4      28      38      48      58      68      78      88  
 80      90      100      110      120      130      140  
 ACTTCGACGCCTACTACTGTCTCCGAGCCTGCCAGTTCCCCTCTGCGGATCACTTCAACAGCACCAACCA  
 \* \* \* \* \*  
 GCTACGCGCGCTACTACTGTGAGGGGGAGTGTGCCTTCCCTCTGAACTCCTACATGAACGCCACCAACCA  
 98      108      118      128      138      148      158  
 150      160      170      180      190      200      210  
 CGCCGTGGTGCAGACCCTGGTGAACAACATGAACCCCGCAAGGTACCCAAGCCCTGCTGCGTGCCCAACC  
 \* \* \* \* \*  
 CGCCATCGTGCAGACGCTGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGCCACG  
 168      178      188      198      208      218      228  
 220      230      240      250      260      270      280  
 GAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATTCCACCGTGGTGCTGAAGAAGTACCAGGAGA  
 \* \* \* \* \*  
 CAGCTCAATGCCATCTCCGTCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGAAACA  
 238      248      258      268      278      288      298  
 290      300      310  
 TGACCGTGGTGGGCTGCGGCTGCCGCTAACTGCA  
 \* \* \* \* \*  
 TGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCCT  
 308      318      328



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 20 1546

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	WO 88 00205 A (GENETICS INST) 14 January 1988 (1988-01-14) * the whole document *	1-7,9-15	C12N15/12 C07K14/51 A61K38/18 A61L27/22 A61L27/54
D,X	EP 0 148 155 A (DOW CHEMICAL CO) 10 July 1985 (1985-07-10) * the whole document *	1-4, 11-15	
X	URIST M R ET AL.: "Preparation and bioassay of bone morphogenetic protein and polypeptide fragments" METHODS IN ENZYMOLOGY, vol. 146, 1987, pages 294-312, XP000565634 * the whole document *	1-4, 11-15	
D,X	URIST M R ET AL.: "Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 81, no. 2, January 1984 (1984-01), pages 371-375, XP002198250 ISSN: 0027-8424 * the whole document *	1-4, 11-15	
A	EP 0 169 016 A (COLLAGEN CORP) 22 January 1986 (1986-01-22) * the whole document *	1-4	
A	EP 0 182 483 A (COLLAGEN CORP) 28 May 1986 (1986-05-28) * the whole document *	1-4, 11-15	
-/--			
-The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>14 May 2002</b>	Examiner <b>van de Kamp, M</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



European Patent  
Office

Application Number

EP 01 20 1546

### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-15 (all partially)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 20 1546

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)	
A	URIST M R ET AL.: "Beta-tricalcium phosphate delivery system for bone morphogenetic protein" CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, PHILADELPHIA, PA, US, vol. 187, July 1984 (1984-07), pages 277-280, XP008003034 * the whole document *	11-15		
A	RUEGER J M ET AL.: "Implant materials for bone-replacement. Comparison of the osteostimulative property of four different agents and their combinations by orthotopic implantation in dogs" CALCIFIED TISSUE INTERNATIONAL, vol. 36, no. SUPPL. 2, 1984, page S69 XP008003109 ISSN: 0171-967X * the whole document *	11-15		
A	PADGETT R W ET AL.: "A transcript from a Drosophila pattern gene predicts a protein homologous to the transforming growth factor-beta family" NATURE, vol. 325, 1987, pages 81-84, XP002036812 ISSN: 0028-0836 * the whole document *	3,4,8		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	WEEKS D L ET AL.: "A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGF-beta" CELL, vol. 51, 4 December 1987 (1987-12-04), pages 861-867, XP000653563 ISSN: 0092-8674 * the whole document *	3,4,8		
-The present search report has been drawn up for all claims				
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>14 May 2002</b>	Examiner <b>van de Kamp, M</b>	
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>				





European Patent  
Office

LACK OF UNITY OF INVENTION  
SHEET B

Application Number  
EP 01 20 1546

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-15 (all partially)

Use of a composition consisting of a single species of osteogenic protein as active osteogenic ingredient, said protein comprising of an unpaired polypeptide chain or which protein does not comprise a pair of polypeptide chains and is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation, wherein the protein comprises the sequence VPKPCCAPT or LYCSF-to-ACGHC or HQRQA-to-ACGHC (according to claim 8a-c). Said osteogenic protein in unglycosylated form, a process for its production, and a polypeptide producible by said process. Said use, protein, process or polypeptide wherein the protein has an apparent molecular weight of 30 kD in the glycosylated native form (27 kD in deglycosylated form), or comprises two polypeptide chains with apparent molecular weights of 16 and 18 kD in glycosylated form (14 to 16 kD in glycosylated form). Processes for producing an osteogenic device comprising disposing said protein in a matrix, for implantation in a mammal.

2. Claims: 1-15 (all partially)

Use of a composition consisting of a single species of osteogenic protein as active osteogenic ingredient, said protein comprising of an unpaired polypeptide chain or which protein does not comprise a pair of polypeptide chains and is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation, wherein the protein comprises the sequence CKRHP-to-GCGCR (according to claim 8d). Said osteogenic protein in unglycosylated form, a process for its production, and a polypeptide producible by said process. Said use, protein, process or polypeptide wherein the protein has an apparent molecular weight of 30 kD in the glycosylated native form (27 kD in deglycosylated form), or comprises two polypeptide chains with apparent molecular weights of 16 and 18 kD in glycosylated form (14 to 16 kD in glycosylated form). Processes for producing an osteogenic device comprising disposing said protein in a matrix, for implantation in a mammal.

3. Claims: 1-15 (all partially)

Use of a composition consisting of a single species of osteogenic protein as active osteogenic ingredient, said protein comprising of an unpaired polypeptide chain or which



European Patent  
Office

LACK OF UNITY OF INVENTION  
SHEET B

Application Number  
EP 01 20 1546

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

protein does not comprise a pair of polypeptide chains and is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation, wherein the protein comprises the sequence CRRHS-to-GCGCR (according to claim 8e). Said osteogenic protein in unglycosylated form, a process for its production, and a polypeptide producible by said process. Said use, protein, process or polypeptide wherein the protein has an apparent molecular weight of 30 kD in the glycosylated native form (27 kD in deglycosylated form), or comprises two polypeptide chains with apparent molecular weights of 16 and 18 kD in glycosylated form (14 to 16 kD in glycosylated form). Processes for producing an osteogenic device comprising disposing said protein in a matrix, for implantation in a mammal.

4. Claims: 1-15 (all partially)

Use of a composition consisting of a single species of osteogenic protein as active osteogenic ingredient, said protein comprising of an unpaired polypeptide chain or which protein does not comprise a pair of polypeptide chains and is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, for the manufacture of a medicament for inducing endochondral bone formation, wherein the protein comprises the sequence CARRY-to-SCACR (according to claim 8f). Said osteogenic protein in unglycosylated form, a process for its production, and a polypeptide producible by said process. Said use, protein, process or polypeptide wherein the protein has an apparent molecular weight of 30 kD in the glycosylated native form (27 kD in deglycosylated form), or comprises two polypeptide chains with apparent molecular weights of 16 and 18 kD in glycosylated form (14 to 16 kD in glycosylated form). Processes for producing an osteogenic device comprising disposing said protein in a matrix, for implantation in a mammal.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 20 1546

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	URIST M R ET AL.: "Bone cell differentiation and growth factors" SCIENCE (WASHINGTON D C), vol. 220, no. 4598, 1983, XP008003037 ISSN: 0036-8075 * the whole document *		
D,P, X	WANG E A ET AL.: "Purification and characterization of other distinct bone-inducing factors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, no. 24, 1 December 1988 (1988-12-01), pages 9484-9488, XP000008758 ISSN: 0027-8424 * the whole document *	3,4,9	
E	WO 90 11366 A (GENETICS INST) 4 October 1990 (1990-10-04) * the whole document *	1-4,7-9, 11-15	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
T	OZKAYNAK E ET AL.: "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family" EMBO JOURNAL, vol. 9, no. 7, 1 July 1990 (1990-07-01), pages 2085-2093, XP000611252 ISSN: 0261-4189 * the whole document *		
-/--			
<del>The present search report has been drawn up for all claims</del>			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>14 May 2002</b>	Examiner <b>van de Kamp, M</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 20 1546

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
T	SAMPATH T K ET AL.: "Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2a, two members of the transforming growth factor-beta superfamily" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 22, 5 August 1990 (1990-08-05), pages 13198-13205, XP000611250 ISSN: 0021-9258 * the whole document *		
T	CELESTE A J ET AL.: "Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 24, 1 December 1990 (1990-12-01), pages 9843-9847, XP000168624 ISSN: 0027-8424 * the whole document *		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
<del>The present search report has been drawn up for all claims</del>			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>14 May 2002</b>	Examiner <b>van de Kamp, M</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ***** & : member of the same patent family, corresponding document	

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 20 1546

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-05-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8800205      A	14-01-1988	US 4877864 A	31-10-1989
		AT 141928 T	15-09-1996
		AU 613314 B2	01-08-1991
		AU 7783587 A	29-01-1988
		DE 3751887 D1	02-10-1996
		DE 3751887 T2	06-03-1997
		DK 53497 A	09-05-1997
		DK 106288 A	28-04-1988
		EP 1254956 A2	06-11-2002
		EP 0313578 A1	03-05-1989
		EP 0688869 A1	27-12-1995
		ES 2007625 A6	01-07-1989
		GR 871028 A1	11-01-1988
		IE 75881 B1	24-09-1997
		IE 970378 L	01-01-1988
		IL 83003 A	31-07-1995
		JP 2729222 B2	18-03-1998
		JP 6298800 A	25-10-1994
		JP 3093682 B2	03-10-2000
		JP 10070989 A	17-03-1998
		JP 2500241 T	01-02-1990
		JP 2713715 B2	16-02-1998
		KR 9705583 B1	18-04-1997
		MX 170919 B	22-09-1993
		NZ 220894 A	28-05-1990
		PT 85225 A ,B	01-08-1987
		WO 8800205 A1	14-01-1988
		US 5543394 A	06-08-1996
		US 5631142 A	20-05-1997
		US 5013649 A	07-05-1991
		US 6207813 B1	27-03-2001
		US 5459047 A	17-10-1995
		US 5166058 A	24-11-1992
		US 5635373 A	03-06-1997
		US 5849880 A	15-12-1998
		US 5187076 A	16-02-1993
		US 6432919 B1	13-08-2002
		US 5618924 A	08-04-1997
		US 5116738 A	26-05-1992
		US 6150328 A	21-11-2000
		US 5366875 A	22-11-1994
		US 5939388 A	17-08-1999
		US 2002061577 A1	23-05-2002
		US 6245889 B1	12-06-2001
		US 6177406 B1	23-01-2001
		NO 880701 A	17-02-1988

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 20 1546

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-05-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date	
WO 8800205	A	NO	963788 A	17-02-1988	
		NO	963789 A	17-02-1988	
		US	5106748 A	21-04-1992	
		US	5108922 A	28-04-1992	
-----					
EP 0148155	A	10-07-1985	AT	42309 T	15-05-1989
		AU	580975 B2	09-02-1989	
		AU	3722184 A	11-07-1985	
		CA	1241641 A1	06-09-1988	
		DE	3569542 D1	24-05-1989	
		DK	2285 A ,B,	05-07-1985	
		EP	0148155 A2	10-07-1985	
		GR	850006 A1	03-05-1985	
		IE	57966 B1	02-06-1993	
		JP	60226814 A	12-11-1985	
		NZ	210699 A	28-06-1989	
		US	4804744 A	14-02-1989	
		ZA	8500047 A	24-09-1986	
-----					
EP 0169016	A	22-01-1986	AT	128715 T	15-10-1995
		AU	592951 B2	01-02-1990	
		AU	4501585 A	23-01-1986	
		AU	594949 B2	22-03-1990	
		AU	5649586 A	29-10-1987	
		CA	1261549 A1	26-09-1989	
		DE	3588058 D1	09-11-1995	
		DE	3588058 T2	02-05-1996	
		EP	0169016 A2	22-01-1986	
		JP	2074953 C	25-07-1996	
		JP	7094474 B	11-10-1995	
		JP	61036223 A	20-02-1986	
		US	4774322 A	27-09-1988	
		US	4774228 A	27-09-1988	
		US	4810691 A	07-03-1989	
		US	4843063 A	27-06-1989	
		US	RE35694 E	16-12-1997	
		US	RE34090 E	06-10-1992	
-----					
EP 0182483	A	28-05-1986	US	4563350 A	07-01-1986
		AT	54830 T	15-08-1990	
		AU	585268 B2	15-06-1989	
		AU	4900585 A	01-05-1986	
		CA	1266613 A1	13-03-1990	
		DE	3578874 D1	30-08-1990	
		EP	0182483 A1	28-05-1986	
		JP	1855544 C	07-07-1994	

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 20 1546

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-05-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0182483	A		JP 5055149 B	16-08-1993
			JP 62016421 A	24-01-1987
			US 4888366 A	19-12-1989
			US 5001169 A	19-03-1991
-----				
WO 9011366	A	04-10-1990	US 5106748 A	21-04-1992
			US 5141905 A	25-08-1992
			US 5187076 A	16-02-1993
			AT 162223 T	15-01-1998
			AU 624940 B2	25-06-1992
			AU 5357790 A	22-10-1990
			CA 2030518 A1	29-09-1990
			DE 69031939 D1	19-02-1998
			DE 69031939 T2	10-09-1998
			DK 429570 T3	27-04-1998
			EP 0429570 A1	05-06-1991
			ES 2113857 T3	16-05-1998
			JP 3505098 T	07-11-1991
			KR 214740 B1	02-08-1999
			KR 239203 B1	15-01-2000
			KR 247216 B1	15-03-2000
			WO 9011366 A1	04-10-1990
			US 5543394 A	06-08-1996
			US 6207813 B1	27-03-2001
			US 5635373 A	03-06-1997
			US 5366875 A	22-11-1994
			US 5939388 A	17-08-1999
			US 2002061577 A1	23-05-2002
			US 5459047 A	17-10-1995
			US 5849880 A	15-12-1998
			MX 9203129 A1	01-07-1992
			MX 9203296 A1	01-07-1992
			MX 9203127 A1	01-07-1992
-----				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**